1
|
Abstract
PURPOSE OF REVIEW Detection of high-impact variants on lipid traits is complicated by complex genetic architecture. Although genome-wide association studies (GWAS) successfully identified many novel genes associated with lipid traits, it was less successful in identifying variants with a large impact on the phenotype. This is not unexpected, as the more common variants detectable by GWAS typically have small effects. The availability of large familial datasets and sequence data has changed the paradigm for successful genomic discovery of the novel genes and pathogenic variants underlying lipid disorders. RECENT FINDINGS Novel loci with large effects have been successfully mapped in families, and next-generation sequencing allowed for the identification of the underlying lipid-associated variants of large effect size. The success of this strategy relies on the simplification of the underlying genetic variation by focusing on large single families segregating extreme lipid phenotypes. SUMMARY Rare, high-impact variants are expected to have large effects and be more relevant for medical and pharmaceutical applications. Family data have many advantages over population-based data because they allow for the efficient detection of high-impact variants with an exponentially smaller sample size and increased power for follow-up studies.
Collapse
Affiliation(s)
- Elisabeth Rosenthal
- Department of Medicine (Medical Genetics), University of Washington, Seattle, Seattle, Washington, USA
| | - Elizabeth Blue
- Department of Medicine (Medical Genetics), University of Washington, Seattle, Seattle, Washington, USA
| | - Gail P. Jarvik
- Department of Medicine (Medical Genetics), University of Washington, Seattle, Seattle, Washington, USA
- Department of Genome Sciences, University of Washington, Seattle, Seattle, Washington, USA
| |
Collapse
|
2
|
A rare variant in APOC3 is associated with plasma triglyceride and VLDL levels in Europeans. Nat Commun 2014; 5:4871. [PMID: 25225788 PMCID: PMC4167609 DOI: 10.1038/ncomms5871] [Citation(s) in RCA: 58] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2014] [Accepted: 07/30/2014] [Indexed: 02/02/2023] Open
Abstract
The analysis of rich catalogues of genetic variation from population-based sequencing provides an opportunity to screen for functional effects. Here we report a rare variant in APOC3 (rs138326449-A, minor allele frequency ~0.25% (UK)) associated with plasma triglyceride (TG) levels (-1.43 s.d. (s.e.=0.27 per minor allele (P-value=8.0 × 10(-8))) discovered in 3,202 individuals with low read-depth, whole-genome sequence. We replicate this in 12,831 participants from five additional samples of Northern and Southern European origin (-1.0 s.d. (s.e.=0.173), P-value=7.32 × 10(-9)). This is consistent with an effect between 0.5 and 1.5 mmol l(-1) dependent on population. We show that a single predicted splice donor variant is responsible for association signals and is independent of known common variants. Analyses suggest an independent relationship between rs138326449 and high-density lipoprotein (HDL) levels. This represents one of the first examples of a rare, large effect variant identified from whole-genome sequencing at a population scale.
Collapse
|
3
|
Brouwers MCGJ, van Greevenbroek MMJ, Stehouwer CDA, de Graaf J, Stalenhoef AFH. The genetics of familial combined hyperlipidaemia. Nat Rev Endocrinol 2012; 8:352-62. [PMID: 22330738 DOI: 10.1038/nrendo.2012.15] [Citation(s) in RCA: 73] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
Almost 40 years after the first description of familial combined hyperlipidaemia (FCHL) as a discrete entity, the genetic and metabolic basis of this prevalent disease has yet to be fully unveiled. In general, two strategies have been applied to elucidate its complex genetic background, the candidate-gene and the linkage approach, which have yielded an extensive list of genes associated with FCHL or its related traits, with a variable degree of scientific evidence. Some genes influence the FCHL phenotype in many pedigrees, whereas others are responsible for the affected state in only one kindred, thereby adding to the genetic and phenotypic heterogeneity of FCHL. This Review outlines the individual genes that have been described in FCHL and how these genes can be incorporated into the current concept of metabolic pathways resulting in FCHL: adipose tissue dysfunction, hepatic fat accumulation and overproduction, disturbed metabolism and delayed clearance of apolipoprotein-B-containing particles. Genes that affect metabolism and clearance of plasma lipoprotein particles have been most thoroughly studied. The adoption of new traits, in addition to the classic plasma lipid traits, could aid in the identification of new genes implicated in other pathways in FCHL. Moreover, systems genetic analysis, which integrates genetic polymorphisms with data on gene expression levels, lipidomics or metabolomics, will attribute functions to genetic variants in addition to revealing new genes.
Collapse
Affiliation(s)
- Martijn C G J Brouwers
- Department of Internal Medicine and Endocrinology, Maastricht University Medical Centre, P. Debyelaan 25, 6229 HX, Maastricht, The Netherlands
| | | | | | | | | |
Collapse
|
4
|
Járomi L, Csöngei V, Polgár N, Rappai G, Szolnoki Z, Maász A, Horvatovich K, Sáfrány E, Sipeky C, Magyari L, Melegh B. Triglyceride level-influencing functional variants of the ANGPTL3, CILP2, and TRIB1 loci in ischemic stroke. Neuromolecular Med 2011; 13:179-86. [PMID: 21691831 DOI: 10.1007/s12017-011-8149-7] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2011] [Accepted: 06/02/2011] [Indexed: 12/19/2022]
Abstract
Stroke is a common multifactorial disease, and the third leading cause of death worldwide, which results in serious long-term mental and physical disability among survivors. The role of affected triglyceride metabolism in the development of ischemic stroke is under extensive investigations. Here, we examined three SNPs, rs12130333 located within the ANGPTL3 locus; rs16996148 residing at the CILP2 gene locus; and rs17321515 at the TRIB1 locus, which were originally reported in association with decreased triglyceride levels; therefore, we investigated their possible protective effect against the development of ischemic stroke. A total of 459 Caucasian stroke patients, stratified as large-vessel, small-vessel, and mixed stroke groups, and 168 control subjects were genotyped using PCR-RFLP methods. As a result, we could not detect any differences in triglyceride or total cholesterol levels in relation to any allelic variants of rs16996148, rs17321515, or rs12130333 SNPs. No correlation was found between the minor alleles rs16996148-T (P = 0.881), rs17321515-G (P = 0.070), or rs12130333-T allele (P = 0.757) and the risk for development of stroke. The data presented here suggest different scale of effect of triglyceride modifier alleles and also their variable susceptibility or protective nature.
Collapse
Affiliation(s)
- Luca Járomi
- Department of Medical Genetics, University of Pécs, Szigeti út 12, 7624, Pécs, Hungary
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Bandegi AR, Firoozrai M, Akbari Eidgahi MR, Kokhaei P. SstI Polymorphism of the Apolipoprotein CIII Gene in Iranian Hyperlipidemic Patients: A Study in Semnan Province. IRANIAN JOURNAL OF BASIC MEDICAL SCIENCES 2011; 14:506-13. [PMID: 23493241 PMCID: PMC3586853] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/23/2010] [Accepted: 08/07/2011] [Indexed: 11/26/2022]
Abstract
OBJECTIVES The Sst-I polymorphic site on the 3' untranslated region of the apo CIII gene, has been previously reported to be associated with hypertriglyceridemia. The aim of the present study was to explore the association between Sst-I polymorphism with plasma lipid and lipoprotein levels in hyperlipidemic (HLP) patients from Semnan province, Iran. MATERIALS AND METHODS Genomic DNA was prepared from 76 patients with HLP and 75 matched healthy subjects. DNA samples were amplified by polymerase chain reaction. The samples were analyzed by restriction fragment length polymorphism (RFLP) method using SstI enzyme. RESULTS The genotype and allelic frequencies for this polymorphism were significantly different between HLP and normolipidemic groups (P< 0.002). Plasma triglyceride (TG) level was higher in both groups, in S2S2 genotype was more than in the S1S1and S1S2 genotypes, however, there was no significant difference in comparison with the control group. Subjects with S1S2 + S2S2 genotypes in compare to S1S1 genotype had odd ratio of 2.8 (95% CI: 1.41-5.56, P< 0.003) for developing hypertriglyceridemia. CONCLUSION The results showed that the presence of rare S2 allele was associated with change in TG level in the selected population.
Collapse
Affiliation(s)
- Ahmad Reza Bandegi
- Department of Biochemistry, Faculty of Medicine, Semnan University of Medical Sciences, Semnan, Iran,Corresponding author: Tel: +98-231-3354171; Fax: +98-231-3354161;
| | - Mohsen Firoozrai
- Department of Biochemistry, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran
| | | | - Parviz Kokhaei
- Immune and Gene Therapy Lab, CCK, Karolinska University Hospital Solna, Stockholm, Sweden,Department of Immunology, Faculty of Medicine, Semnan University of Medical Sciences, Semnan, Iran
| |
Collapse
|
6
|
Clarke H, Mousa SA. The implications of pharmacogenomics in the treatment of HIV-1-infected patients of African descent. PHARMACOGENOMICS & PERSONALIZED MEDICINE 2009; 2:93-9. [PMID: 23226038 PMCID: PMC3513205 DOI: 10.2147/pgpm.s5824] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 09/09/2009] [Indexed: 01/01/2023]
Abstract
One of the great advances in the treatment of HIV-1 infection was the development of the highly active antiretroviral therapy (HAART). Although this treatment strategy is highly effective in many individuals, interpatient variability of drug response and high incidences of short- and long-term toxicities remain significant problems associated with this treatment. Logically, pharmacogenetic differences among HIV-1-infected individuals are thought to represent important factors contributing to antiretroviral drug response. Studies have identified polymorphisms in drug-metabolizing enzymes, drug transporters, and most recently the human leukocyte antigen locus that appears to have significant effects on the clinical outcomes of antiretroviral therapy. Furthermore, some studies have shown that many of these crucial polymorphisms are more likely or less likely in certain populations. This review investigates the potential role of pharmacogenomics in the management of HIV-1 infection in people of African descent.
Collapse
Affiliation(s)
- Hector Clarke
- The Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Rensselaer, NY, USA
| | | |
Collapse
|
7
|
Turner ST, Fornage M, Jack CR, Mosley TH, Knopman DS, Kardia SLR, Boerwinkle E, de Andrade M. Genomic susceptibility Loci for brain atrophy, ventricular volume, and leukoaraiosis in hypertensive sibships. ACTA ACUST UNITED AC 2009; 66:847-57. [PMID: 19597086 DOI: 10.1001/archneurol.2009.110] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
OBJECTIVE To localize susceptibility genes for alterations in brain structure associated with risk of stroke and dementia. We conducted genomewide linkage analyses for magnetic resonance imaging (MRI) measures of brain atrophy, ventricular, and subcortical white matter hyperintensity (leukoaraiosis) in 689 non-Hispanic white (673 sibling pairs; median age, 61 years) and 544 non-Hispanic black participants (503 sibling pairs; median age, 64 years) from sibships with at least 2 members with essential hypertension. DESIGN, SETTING, AND PATIENTS We determined brain, ventricular, and leukoaraiosis volumes from axial fluid-attenuated inversion recovery MRI; we calculated brain atrophy as the difference between total intracranial and brain volumes. Microsatellite markers (n = 451) distributed across the 22 autosomes were genotyped, and we used variance components methods to estimate heritability and assess evidence of genetic linkage for each MRI measure. MAIN OUTCOME MEASURES Brain atrophy ventricular volume, and leukoaraiosis determined from fluid-attenuated inversion recovery MRI. RESULTS In both races, the heritability of each MRI measure was statistically greater than 0 (P < .001), ranging in magnitude from 0.42 (for ventricular volume in blacks) to 0.69 (for brain atrophy in blacks). Based on multipoint logarithm of odds scores (MLS), the strongest evidence of genetic linkage was observed for brain atrophy on chromosomes 1 (MLS, 3.49 at 161 cM; P < .001) and 17 (MLS, 3.08 at 18 cM; P < .001) in whites; for ventricular volume on chromosome 12 (MLS, 3.67 at 49 cM; P < .001) in blacks and chromosome 10 (MLS, 2.47 at 110 cM; P < .001) in whites; and for leukoaraiosis on chromosome 11 (MLS, 2.21 at 118 cM; P < .001) in whites and chromosome 22 (MLS, 2.02 at 36 cM; P = .001) in blacks. CONCLUSIONS The MRI measures of structural brain injury are heritable in non-Hispanic black and white sibships ascertained through hypertensive sibling pairs. The susceptibility loci for brain atrophy, ventricular volume, and leukoaraiosis identified by linkage analyses differ among MRI measures and between races.
Collapse
Affiliation(s)
- Stephen T Turner
- Division of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA.
| | | | | | | | | | | | | | | |
Collapse
|
8
|
Shanker J, Perumal G, Rao VS, Khadrinarasimhiah NB, John S, Hebbagodi S, Mukherjee M, Kakkar VV. Genetic studies on the APOA1-C3-A5 gene cluster in Asian Indians with premature coronary artery disease. Lipids Health Dis 2008; 7:33. [PMID: 18801202 PMCID: PMC2556320 DOI: 10.1186/1476-511x-7-33] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2008] [Accepted: 09/19/2008] [Indexed: 01/25/2023] Open
Abstract
BACKGROUND The APOA1-C3-A5 gene cluster plays an important role in the regulation of lipids. Asian Indians have an increased tendency for abnormal lipid levels and high risk of Coronary Artery Disease (CAD). Therefore, the present study aimed to elucidate the relationship of four single nucleotide polymorphisms (SNPs) in the Apo11q cluster, namely the -75G>A, +83C>T SNPs in the APOA1 gene, the Sac1 SNP in the APOC3 gene and the S19W variant in the APOA5 gene to plasma lipids and CAD in 190 affected sibling pairs (ASPs) belonging to Asian Indian families with a strong CAD history. METHODS & RESULTS Genotyping and lipid assays were carried out using standard protocols. Plasma lipids showed a strong heritability (h2 48% - 70%; P < 0.0001). A subset of 77 ASPs with positive sign of Logarithm of Odds (LOD) score showed significant linkage to CAD trait by multi-point analysis (LOD score 7.42, P < 0.001) and to Sac1 (LOD score 4.49) and -75G>A (LOD score 2.77) SNPs by single-point analysis (P < 0.001). There was significant proportion of mean allele sharing (pi) for the Sac1 (pi 0.59), -75G>A (pi 0.56) and +83C>T (pi 0.52) (P < 0.001) SNPs, respectively. QTL analysis showed suggestive evidence of linkage of the Sac1 SNP to Total Cholesterol (TC), High Density Lipoprotein-cholesterol (HDL-C) and Apolipoprotein B (ApoB) with LOD scores of 1.42, 1.72 and 1.19, respectively (P < 0.01). The Sac1 and -75G>A SNPs along with hypertension showed maximized correlations with TC, TG and Apo B by association analysis. CONCLUSION The APOC3-Sac1 SNP is an important genetic variant that is associated with CAD through its interaction with plasma lipids and other standard risk factors among Asian Indians.
Collapse
Affiliation(s)
- Jayashree Shanker
- Mary and Garry Weston Functional Genomics Unit, Thrombosis Research Institute, Bangalore, India.
| | | | | | | | | | | | | | | |
Collapse
|
9
|
Parzianello L, Oliveira G, Coelho J. Apolipoprotein CIII polymorphism and triglyceride levels of a Japanese population living in Southern Brazil. Braz J Med Biol Res 2008; 41:462-7. [DOI: 10.1590/s0100-879x2008005000022] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2007] [Accepted: 04/30/2008] [Indexed: 11/21/2022] Open
Affiliation(s)
- L. Parzianello
- Universidade Federal do Rio Grande do Sul, Brasil; Laboratório Parzianello, Brasil
| | | | - J.C. Coelho
- Universidade Federal do Rio Grande do Sul, Brasil; Hospital de Clínicas de Porto Alegre, Brasil
| |
Collapse
|
10
|
Pullinger CR, Aouizerat BE, Movsesyan I, Durlach V, Sijbrands EJ, Nakajima K, Poon A, Dallinga-Thie GM, Hattori H, Green LL, Kwok PY, Havel RJ, Frost PH, Malloy MJ, Kane JP. An apolipoprotein A-V gene SNP is associated with marked hypertriglyceridemia among Asian-American patients. J Lipid Res 2008; 49:1846-54. [PMID: 18441017 DOI: 10.1194/jlr.p800011-jlr200] [Citation(s) in RCA: 53] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Apolipoprotein A-V (apoA-V) is an important regulator of plasma levels of triglyceride (TG) in mice. In humans, APOA5 genetic variation is associated with TG in several populations. In this study, we determined the effects of the p.185Gly>Cys (c.553G>T; rs2075291) polymorphism on plasma TG levels in subjects of Chinese ancestry living in the United States and in a group of non-Chinese Asian ancestry. The frequency of the less common cysteine allele was 4-fold higher (15.1% vs. 3.7%) in Chinese high-TG subjects compared with a low-TG group (Chi-square = 20.2; P < 0.0001), corresponding with a 4.45 times higher risk of hypertriglyceridemia (95% confidence interval, 2.18-9.07; P < 0.001). These results were replicated in the non-Chinese Asians. Heterozygosity was associated, in the high-TG group, with a doubling of TG (P < 0.001), mainly VLDL TG (P = 0.014). All eleven TT homozygotes had severe hypertriglyceridemia, with mean TG of 2,292 +/- 447 mg/dl. Compared with controls, carriers of the T allele had lower postheparin lipoprotein lipase activity but not hepatic lipase activity. In Asian populations, this common polymorphism can lead to profound adverse effects on lipoprotein profiles, with homozygosity accounting for a significant number of cases of severe hypertriglyceridemia. This specific apoA-V variant has a pronounced effect on TG metabolism, the mechanism of which remains to be elucidated.
Collapse
Affiliation(s)
- Clive R Pullinger
- Cardiovascular Research Institute, University of California, San Francisco, CA, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Chien KL, Chen MF, Hsu HC, Su TC, Chang WT, Lee CM, Lee YT. Genetic association study of APOA1/C3/A4/A5 gene cluster and haplotypes on triglyceride and HDL cholesterol in a community-based population. Clin Chim Acta 2007; 388:78-83. [PMID: 17964293 DOI: 10.1016/j.cca.2007.10.006] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2005] [Revised: 10/04/2007] [Accepted: 10/04/2007] [Indexed: 01/08/2023]
Abstract
BACKGROUND Polymorphism of apolipoprotein A1/C3/A4/A5 gene cluster affected lipid profiles in general population. We reported 6 polymorphisms, APOA1 -75G>A, APOA1 83C>T, APOC3 3175C>G, APOC3 3206G>T, APOA4 127A>G, and APOA5 553G>T in APOA1/C3/A4/A5 gene and the haplotype structures on triglyceride and HDL traits among ethnic Chinese. RESULTS Overall, there were statistically significant differences in the distribution of APOA1 -75G>A and APOA5 +553G>T genotypes comparing cases with control subjects. For the APOA1 -75 SNP, a lower risk of triglyceride/HDL among subjects with A/A genotype compared with those with the G/G genotype (odds ratio, OR=0.39, 95% CI 0.16-0.92, P=0.04). However, the risk magnitude reduced after multivariate adjustments. For continuous traits, we found that only in APOA5 +553 T allele carriers showed a significant higher triglyceride and a significant lower HDL cholesterol level than subjects with APOA5 +553 G/G genotypes. There were significant differences in overall haplotype frequencies between case and control subjects (P<0.001). CONCLUSION There is an important role of APOA1/C3/A4/A5 gene polymorphisms and haplotypes in the development of high triglyceride/HDL ratio in Chinese.
Collapse
Affiliation(s)
- Kuo-Liong Chien
- Institute of Preventive Medicine, School of Public Health, National Taiwan University, Taiwan
| | | | | | | | | | | | | |
Collapse
|
12
|
Pei WD, Zhang YH, Sun YH, Gu YC, Wang YF, Zhang CY, Zhang J, Liu LS, Hui RT, Liu YQ, Yang YJ. Apolipoprotein E polymorphism influences lipid phenotypes in Chinese families with familial combined hyperlipidemia. Circ J 2007; 70:1606-10. [PMID: 17127808 DOI: 10.1253/circj.70.1606] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
BACKGROUND Apolipoprotein E (apoE) polymorphism is associated with changes in the lipoprotein profile of individuals with familial combined hyperlipidemia (FCHL), but its effects on the lipoprotein profiles of members of Chinese families with FCHL remain uncertain. METHODS AND RESULTS 43 FCHL families (n=449) and 9 normolipidemic families (n=73) were recruited to assess the influence of apoE polymorphism on plasma lipids. The relative frequency of the epsilon4 allele in affected and unaffected FCHL relatives, spouses and normolipidemic members was 13.8%, 5.3%, 9.1% and 6.8%, respectively, with a significantly higher frequency in affected FCHL relatives, compared with unaffected FCHL relatives or normolipidemic members (p=0.0002 or p=0.029). In FCHL relatives, the apoE4 subset (E4/4 and E4/3) exhibited significantly higher levels of apoB, total cholesterol and low-density lipoprotein-cholesterol (LDL-C) than did the apoE3 (E3/3) subset, especially in women (all p<0.05), and there was significant elevation of LDL-C concentrations in men only (p<0.05). In men, the apoE2 (E3/2) subset indicated a decreased level of apoB and increased apoA1 compared with those in the apoE3 subset (p<0.05). CONCLUSIONS ApoE polymorphism appears to be associated with variance of the lipoprotein phenotype in Chinese families with FCHL.
Collapse
Affiliation(s)
- Wei-Dong Pei
- Division of Cardiology, Cardiovascular Institute and Fu Wai Heart Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Huang MC, Wang TN, Liu YL, Pa TH, Tu HP, Huang YC, Chang WT, Ko YC. Effect of SstI polymorphism of the apolipoprotein CIII gene and environmental factors on risks of hypertriglyceridemia in Taiwan aborigines. Circ J 2006; 70:1030-6. [PMID: 16864937 DOI: 10.1253/circj.70.1030] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
BACKGROUND Hypertriglyceridemia (HTG) is a heterogeneous metabolic disorder. The aim of this study was to examine associations among genetic polymorphisms, SstI polymorphism of apolipoprotein CIII (ApoCIII) and Hind III polymorphism of lipoprotein lipase (LPL), environmental factors and risks of HTG. METHODS AND RESULTS Two hundred and forty-nine southern Taiwanese aborigines were recruited for a cross-sectional study, which included 90 subjects with triglyceride (TG)>150 mg/dl (HTG) and 159 with TG<or=150 mg/dl (NTG). The frequencies of SstI major allele (S1) and minor allele (S2) of ApoCIII were 66.1% and 33.9% in HTG and 73.6% and 26.4% in NTG (p<0.1). In female subjects, the frequencies of the S2 allele was significantly higher in HTG (0.38) than NTG (0.27) (p<0.04). The frequencies of the LPL HindIII major allele (H+) and minor allele (H-) were similar between HTG (H+ 84.3%; H- 15.7%) and NTG (H+ 78.9%; H- 21.1%). In a multivariate adjusted logistic model, education<or=6 year (odds ratio (OR)=3.71, 95% confidence interval (CI): 1.24-8.13), Amis tribe (OR=3.08, 95% CI: 1.41-6.77), body mass index (BMI)>or=25 (OR=2.22, 95% CI: 1.18-4.16), starchy food consumption>or=3 times/week (OR=1.89, 95% CI: 1.00-3.59) and ApoCIII S2S2 genotype (OR=3.35, 95% CI: 1.10-10.19) were independently (p<0.05) associated with HTG risks. Among ApoCIII S1S1, S1S2 and S2S2 genotypes, ApoCIII and TG concentrations increased (p<0.01) in a dose-responsive manner. CONCLUSIONS The ApoCIII S2 variant and environmental factors, including education, tribal background, BMI and starchy food intake, modulate the risks of HTG in aboriginal Taiwanese. Interaction between genetic and environmental factors warrants further investigation.
Collapse
Affiliation(s)
- Meng-Chuan Huang
- Department of Public Health, School of Medicine, Kaohsiung Medical University, Chung-Ho Memorial Hospital, Taiwan
| | | | | | | | | | | | | | | |
Collapse
|
14
|
Foulkes AS, Wohl DA, Frank I, Puleo E, Restine S, Wolfe ML, Dube MP, Tebas P, Reilly MP. Associations among race/ethnicity, ApoC-III genotypes, and lipids in HIV-1-infected individuals on antiretroviral therapy. PLoS Med 2006; 3:e52. [PMID: 16417409 PMCID: PMC1334223 DOI: 10.1371/journal.pmed.0030052] [Citation(s) in RCA: 69] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/09/2005] [Accepted: 11/18/2005] [Indexed: 02/06/2023] Open
Abstract
BACKGROUND Protease inhibitors (PIs) are associated with hypertriglyceridemia and atherogenic dyslipidemia. Identifying HIV-1-infected individuals who are at increased risk of PI-related dyslipidemia will facilitate therapeutic choices that maintain viral suppression while reducing risk of atherosclerotic diseases. Apolipoprotein C-III (apoC-III) gene variants, which vary by race/ethnicity, have been associated with a lipid profile that resembles PI-induced dyslipidemia. However, the association of race/ethnicity, or candidate gene effects across race/ethnicity, with plasma lipid levels in HIV-1-infected individuals, has not been reported. METHODS AND FINDINGS A cross-sectional analysis of race/ethnicity, apoC-III/apoA-I genotypes, and PI exposure on plasma lipids was performed in AIDS Clinical Trial Group studies (n = 626). Race/ethnicity was a highly significant predictor of plasma lipids in fully adjusted models. Furthermore, in stratified analyses, the effect of PI exposure appeared to differ across race/ethnicity. Black/non-Hispanic, compared with White/non-Hispanics and Hispanics, had lower plasma triglyceride (TG) levels overall, but the greatest increase in TG levels when exposed to PIs. In Hispanics, current PI antiretroviral therapy (ART) exposure was associated with a significantly smaller increase in TGs among patients with variant alleles at apoC-III-482, -455, and Intron 1, or at a composite apoC-III genotype, compared with patients with the wild-type genotypes. CONCLUSIONS In the first pharmacogenetic study of its kind in HIV-1 disease, we found race/ethnic-specific differences in plasma lipid levels on ART, as well as differences in the influence of the apoC-III gene on the development of PI-related hypertriglyceridemia. Given the multi-ethnic distribution of HIV-1 infection, our findings underscore the need for future studies of metabolic and cardiovascular complications of ART that specifically account for racial/ethnic heterogeneity, particularly when assessing candidate gene effects.
Collapse
Affiliation(s)
- Andrea S Foulkes
- School of Public Health and Health Sciences, University of Massachusetts, Amherst, Massachusetts, United States of America.
| | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Abstract
Familial combined hyperlipidemia (FCHL) constitutes a substantial risk factor for atherosclerosis since it is observed in about 20% of coronary heart disease (CHD) patients under 60 years. FCHL, characterized by elevated levels of total cholesterol (TC) and triglycerides (TGs), or both, is also one of the most common familial hyperlipidemias with a prevalence of 1%-6% in Western populations. Numerous studies have been performed to identify genes contributing to FCHL. The recent linkage and association studies and their replications are beginning to elucidate the genetic variations underlying the susceptibility to FCHL. Three chromosomal regions on 1q21-23, 11p and 16q22-24.1 have been replicated in different study samples, offering targets for gene hunting. In addition, several candidate gene studies have replicated the influence of the lipoprotein lipase (LPL) gene and apolipoprotein A1/C3/A4/A5 (APOA1/C3/A4/A5) gene cluster in FCHL. Recently, the linked region on chromosome 1q21 was successfully fine-mapped and the upstream transcription factor 1 (USF1) gene identified as the underlying gene for FCHL. This finding has now been replicated in independent FCHL samples. However, the total number of variants, the risk related to each variant and their relative contributions to the disease susceptibility are not known yet.
Collapse
Affiliation(s)
- Elina Suviolahti
- Department of Human Genetics, David Geffen School of Medicine at UCLA, University of California, Los Angeles, CA 90095-7088, USA
| | | | | |
Collapse
|
16
|
Lin W, Yang HH, Lee MP. Allelic variation in gene expression identified through computational analysis of the dbEST database. Genomics 2005; 86:518-27. [PMID: 15993562 DOI: 10.1016/j.ygeno.2005.05.004] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2004] [Revised: 05/07/2005] [Accepted: 05/22/2005] [Indexed: 11/21/2022]
Abstract
Differential expression between the two alleles of an individual and between people with different genotypes has been commonly observed. Quantitative differences in gene expression between people may provide the genetic basis for the phenotypic difference between individuals and may be the primary cause of complex diseases. In this paper, we developed a computational method to identify genes that displayed allelic variation in gene expression in human EST libraries. To model allele-specific gene expression, we first identified EST libraries in which both A and B alleles were expressed and then identified allelic variation in gene expression based on the EST counts for each allele using a binomial test. Among 1107 SNPs that had a sufficient number of ESTs for the analysis, 524 (47%) displayed allelic variation in at least one cDNA library. We verified experimentally the allelic variation in gene expression for 6 of these SNPs. The frequency of allelic variation observed in EST libraries was similar to the previous studies using the SNP chip and primer extension method. We found that genes that displayed allelic variation were distributed throughout the human genome and were enriched in certain chromosome regions. The SNPs and genes identified in this study will provide a rich source for evaluating the effects of those SNPs and associated haplotypes in human health and diseases.
Collapse
Affiliation(s)
- Wei Lin
- Laboratory of Population Genetics, National Cancer Institute, Bethesda, MD 20892, USA
| | | | | |
Collapse
|
17
|
Liu S, Song Y, Hu FB, Niu T, Ma J, Gaziano M, Stampfer MJ. A prospective study of the APOA1 XmnI and APOC3 SstI polymorphisms in the APOA1/C3/A4 gene cluster and risk of incident myocardial infarction in men. Atherosclerosis 2005; 177:119-26. [PMID: 15488874 DOI: 10.1016/j.atherosclerosis.2004.07.002] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/26/2004] [Accepted: 07/02/2004] [Indexed: 10/26/2022]
Abstract
BACKGROUND Apolipoproteins AI/CIII/AIV play important roles in the metabolism of triglycerides (TG) and high-density lipoprotein (HDL) cholesterol. However, whether genetic variations in the APOA1/C3/A4 gene cluster are associated with the risk of myocardial infarction (MI) remains uncertain and prospective data are sparse. METHODS In a prospective nested case-control study of 385 incident cases of MI and 373 age- and smoking-matched controls from the Physicians' Health Study, we examined the relationship between 2 common single nucleotide polymorphisms (APOA1 XmnI and APOC3 SstI) in the APOA1/C3/A4 gene cluster and haplotypes defined by these SNPs and risk of incident MI. RESULTS No significant differences in allele or genotype frequency for the APOA1 XmnI and APOC3 SstI polymorphisms were detected between cases and controls. After adjusting for non-lipid coronary risk factors, the relative risks for incident MI were 1.00 (95% CI 0.68-1.47) for men carrying the X2 allele compared with those homozygous for the X1 allele in the APOA1 XmnI site and 1.07 (95% CI 0.69-1.64) for men carrying the S2 versus those homozygous for the S1 allele in the APOC3 SstI site. Moreover, we did not observe any effect modification by HDL or TG levels for the associations of these APOA1 and APOC3 genotypes with MI risk. There were significant differences in TG levels among men carrying different haplotypes (P=0.01) and men carrying the X1-S2 haplotype had higher levels of TG than those carrying the X2-S1 haplotype (202 mg/dl versus 157 mg/dl, P=0.03); however, haplotype frequencies defined by these two polymorphisms did not differ significantly between cases and controls. CONCLUSION In this prospective study of apparently healthy middle-aged US men, carriers of the X1-S2 haplotype in the APOA1 XmnI and APOC3 SstI variants across the APOA1/C3/A4 gene cluster had higher TG levels, but there was no evidence for significant associations between these two common variants or haplotypes defined by them and risk of incident MI in this cohort.
Collapse
Affiliation(s)
- Simin Liu
- Department of Medicine, Division of Preventive Medicine, Brigham and Women's Hospital and Harvard Medical School, 900 Commonwealth Avenue East, Boston, MA 02215, USA.
| | | | | | | | | | | | | |
Collapse
|
18
|
Sun Y, Shi J, Zhang S, Tang M, Han H, Guo Y, Ma C, Liu X, Li T. The APOC3 SstI polymorphism is weakly associated with sporadic Alzheimer's disease in a Chinese population. Neurosci Lett 2005; 380:219-22. [PMID: 15862889 DOI: 10.1016/j.neulet.2005.01.038] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2004] [Revised: 12/26/2004] [Accepted: 01/13/2005] [Indexed: 02/05/2023]
Abstract
In order to clarify the relationship of apolipoprotein CIII (APOC3) polymorphism and sporadic Alzheimer's disease (AD) in Chinese, 165 sporadic AD patients and 174 age-matched elderly individuals were genotyped for the APOC3 SstI and apolipoprotein E (APOE) HhaI polymorphisms. As the result, the APOC3 3017G allele was found to be associated with AD in APOE epsilon4 allele noncarriers (chi2=4.433, P=0.035), and the risk estimate of allele C versus G resulted in an OR of 1.56 (95% CI: 1.03-2.37), although in total no significant differences of allelic or genotypic frequencies between patients and controls were found. Assessment of interaction between APOE epsilon4 and APOC3 3017G status presented an adjusted odds ratio of 0.62 (95% CI: 0.37-1.03) with a borderline significant P-value (P=0.066). Therefore, we conclude that the rare APOC3 G allele may offer some protection against the development of sporadic AD in APOE epsilon4 noncarriers in Chinese.
Collapse
Affiliation(s)
- Yan Sun
- Department of Medical Genetics, West China Hospital, Sichuan University and Division of Human Morbid Genomics, State Key Laboratory of Biotherapy of Human Diseases, Chengdu 610041, China.
| | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Chhabra S, Narang R, Lakshmy R, Vasisht S, Agarwal DP, Srivastava LM, Manchanda SC, Das N. Apolipoprotein C3 SstI polymorphism in the risk assessment of CAD. Mol Cell Biochem 2005; 259:59-66. [PMID: 15124908 DOI: 10.1023/b:mcbi.0000021345.31556.c9] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Various population studies have reported the association of rare S2 allele of apolipoprotein C3 (APOC3) SstI polymorphism with hypertriglyceridemia (HTG) and coronary artery disease (CAD). We were the first to report an association of S2 allele with high triglyceride (TG) levels in healthy volunteers from Northern India. Since HTG is suggested to be a predominant risk factor for CAD among Indians, we have elucidated the relationship of APOC3 SstI polymorphism with the lipid profile and CAD. A total of 158 patients with > or = 70% stenosis in one or more coronary artery (angiographically proven CAD patients), 35 subjects with < 70% stenosis (NCAD) and 151 normal controls (free of heart disease) from Northern plains of India were recruited in the study. DNA samples were analyzed by polymerase chain reaction (PCR) followed by SstI digestion. Lipid profile was estimated by enzymatic kit. We found a strong association of S2 allele with high TG levels, which was more significant in patients. Prevalence of S2 allele in normal controls and CAD patients were comparable, despite the fact that mean TG level was significantly higher in patients. A greater insight into this observation revealed that the prevalence of high TG, if not coupled with other risk factors (like high total cholesterol, low HDL), was comparable in patients and controls. Thus, our study reveals that rare S2 allele may be employed as a susceptibility marker for high TG. However, high TG or S2 allele alone may not contribute to the etiology of CAD.
Collapse
Affiliation(s)
- S Chhabra
- Department of Biochemistry, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India
| | | | | | | | | | | | | | | |
Collapse
|
20
|
Arai H, Yamamoto A, Matsuzawa Y, Saito Y, Yamada N, Oikawa S, Mabuchi H, Teramoto T, Sasaki J, Nakaya N, Itakura H, Ishikawa Y, Ouchi Y, Horibe H, Egashira T, Hattori H, Shirahashi N, Kita T. Polymorphisms in Four Genes Related to Triglyceride and HDL-cholesterol Levels in the General Japanese Population in 2000. J Atheroscler Thromb 2005; 12:240-50. [PMID: 16205020 DOI: 10.5551/jat.12.240] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
Abstract
We studied the association of six common polymorphisms of four genes related to lipid metabolism with serum lipid levels. We selected single-nucleotide polymorphisms (SNPs) in the genes for cholesteryl ester transfer protein (CETP), lipoprotein lipase (LPL), hepatic lipase (LIPC), and apolipoprotein CIII (APOC3), and studied 2267 individuals randomly selected from the participants of Serum Lipid Survey 2000. There was a significant association of CETP polymorphism (D442G, Int14 +1 G --> A, and TaqIB), LPL polymorphism (S447X), and LIPC polymorphism (-514 --> CT) with HDL-cholesterol levels. We also found a significant association of LPL polymorphism (S447X) and APOC3 polymorphism (SstI) with triglyceride levels. This is the largest database showing the association of common genetic variants in lipid metabolism with serum lipid levels in the general Japanese population. Further study is necessary to elucidate the role of these gene polymorphisms in cardiovascular events.
Collapse
Affiliation(s)
- Hidenori Arai
- Department of Geriatric Medicine, Kyoto University School of Medicine, 54 Kawahara-cho, Shogoin, Sakuo-ku, Kyoto 606-8507, Japan.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Sorkin SC, Forestiero FJ, Hirata MH, Guzmán ECR, Cavalli SA, Bertolami MC, Salazar LA, Hirata RDC. APOA1 polymorphisms are associated with variations in serum triglyceride concentrations in hypercholesterolemic individuals. Clin Chem Lab Med 2005; 43:1339-45. [PMID: 16309370 DOI: 10.1515/cclm.2005.229] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
AbstractBackground: Apolipoprotein A-I gene (Methods:Results: G–75A polymorphism was associated with differences in serum concentrations of triglyceride and very low-density lipoprotein (VLDL)-cholesterol (p=0.026) in HC men. After atorvastatin treatment, women carrying theConclusion: Our data suggest that
Collapse
Affiliation(s)
- Simone C Sorkin
- Department of Clinical and Toxicological Analysis, School of Pharmaceutical Sciences, University of Sao Paulo, Sao Paulo, Brazil
| | | | | | | | | | | | | | | |
Collapse
|
22
|
Garenc C, Aubert S, Laroche J, Girouard J, Vohl MC, Bergeron J, Rousseau F, Julien P. Population prevalence of APOE, APOC3 and PPAR-α mutations associated to hypertriglyceridemia in French Canadians. J Hum Genet 2004; 49:691-700. [PMID: 15549499 DOI: 10.1007/s10038-004-0208-6] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2004] [Accepted: 09/22/2004] [Indexed: 10/26/2022]
Abstract
Hypertriglyceridemia (HTG) is known as a common metabolic disorder associated with increased production, decrease catabolism and/or decreased hepatic uptake of triglyceride (TG)-rich particles. We assessed, in the Quebec City population, the allele frequency and haplotype distributions of mutations in genes related to HTG, such as the apolipoprotein E (APOE) (C112R and C158R), the apolipoprotein CIII (APOC3) (C-482T and C3238G) and the peroxisome proliferator-activated receptor alpha (PPARalpha) (L162V) genes. A total of 938 anonymous unlinked newborns from the metropolitan Quebec City area have been genotyped. Allele frequencies observed in the Quebec City population differed from known frequencies determined in other Caucasian populations. The co-transmitted allele distribution between the two-marker genotypes APOE/APOC3(C3238G) and APOC3(C-482T)/PPARalpha(L162V) presented a weak deviation from the assumption of genetic independence. Also, we observed a non-independent distribution of the T-482/G3238 allele combinations within the APOC3 gene, suggesting strong linkage disequilibrium between the C-482T and C3238G polymorphisms. Moreover, comparisons of allele frequencies observed in the population of Québec City to those obtained in other Caucasian populations suggested that the population of Québec City may be at a lower risk of developing HTG due to APOE, APOC3 and PPARalpha genetic variants. However, the strong linkage disequilibrium and the two-marker genotype distributions observed in the APOC3 gene suggest that these two variants may functionally interact in the Québec City population.
Collapse
Affiliation(s)
- Christophe Garenc
- Department of Medicine, Lipid Research Center (CRML), Centre de Recherche du Centre Hospitalier de l'Université Laval du CHUQ, Pavilion CHUL, TR-93, Laval University, 2705 Boulevard Laurier, Sainte-Foy, QC, G1V 4G2, Canada
| | - Samuel Aubert
- Department of Medicine, Lipid Research Center (CRML), Centre de Recherche du Centre Hospitalier de l'Université Laval du CHUQ, Pavilion CHUL, TR-93, Laval University, 2705 Boulevard Laurier, Sainte-Foy, QC, G1V 4G2, Canada
| | - Jèrôme Laroche
- Department of Medical Biology, Faculty of Medicine, Unité de Recherche en Génétique Humaine et Moléculaire, Center for the Development, Evaluation and Rational Implementation of Diagnostic Tests (CEDERINDT), Centre de Recherche de l'Hôpital St-François d'Assise du CHUQ, Laval University, Québec, QC, Canada
- Bioinformatic Center, Laval University, QC, Canada
| | - Joël Girouard
- Department of Medical Biology, Faculty of Medicine, Unité de Recherche en Génétique Humaine et Moléculaire, Center for the Development, Evaluation and Rational Implementation of Diagnostic Tests (CEDERINDT), Centre de Recherche de l'Hôpital St-François d'Assise du CHUQ, Laval University, Québec, QC, Canada
| | - Marie-Claude Vohl
- Department of Medicine, Lipid Research Center (CRML), Centre de Recherche du Centre Hospitalier de l'Université Laval du CHUQ, Pavilion CHUL, TR-93, Laval University, 2705 Boulevard Laurier, Sainte-Foy, QC, G1V 4G2, Canada
| | - Jean Bergeron
- Department of Medicine, Lipid Research Center (CRML), Centre de Recherche du Centre Hospitalier de l'Université Laval du CHUQ, Pavilion CHUL, TR-93, Laval University, 2705 Boulevard Laurier, Sainte-Foy, QC, G1V 4G2, Canada
| | - François Rousseau
- Department of Medical Biology, Faculty of Medicine, Unité de Recherche en Génétique Humaine et Moléculaire, Center for the Development, Evaluation and Rational Implementation of Diagnostic Tests (CEDERINDT), Centre de Recherche de l'Hôpital St-François d'Assise du CHUQ, Laval University, Québec, QC, Canada
| | - Pierre Julien
- Department of Medicine, Lipid Research Center (CRML), Centre de Recherche du Centre Hospitalier de l'Université Laval du CHUQ, Pavilion CHUL, TR-93, Laval University, 2705 Boulevard Laurier, Sainte-Foy, QC, G1V 4G2, Canada.
| |
Collapse
|
23
|
Morello F, de Bruin TWA, Rotter JI, Pratt RE, van der Kallen CJH, Hladik GA, Dzau VJ, Liew CC, Chen YDI. Differential Gene Expression of Blood-Derived Cell Lines in Familial Combined Hyperlipidemia. Arterioscler Thromb Vasc Biol 2004; 24:2149-54. [PMID: 15388524 DOI: 10.1161/01.atv.0000145978.70872.63] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
OBJECTIVES The genetic background of familial combined hyperlipidemia (FCHL) is currently unclear. We propose transcriptional profiling as a complementary tool for its understanding. Two hypotheses were tested: the existence of a disease-specific modification of gene expression in FCHL and the detectability of such a transcriptional profile in blood derived cell lines. METHODS AND RESULTS We established lymphoblastic cell lines from FCHL patients and controls. The cells were cultured in fixed conditions and their basal expression profile was compared using microarrays; 166 genes were differentially expressed in FCHL-derived cell lines compared with controls, with enrichment in metabolism-related genes. Of note was the upregulation of EGR-1, previously found to be upregulated in the adipose tissue of FCHL patients, the upregulation of DCHR-7, the downregulation of LYPLA2, and the differential expression of several genes previously unrelated to FCHL. A cluster of potential EGR-1-regulated transcripts was also differentially expressed in FCHL cells. CONCLUSIONS Our data indicate that in FCHL, a disease-specific transcription profile is detectable in immortalized cell lines easily obtained from peripheral blood and provide complementary information to classical genetic approaches to FCHL and/or the metabolic syndrome.
Collapse
Affiliation(s)
- Fulvio Morello
- Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Huertas-Vázquez A, del Rincón JP, Canizales-Quinteros S, Riba L, Vega-Hernández G, Ramírez-Jiménez S, Aurón-Gómez M, Gómez-Pérez FJ, Aguilar-Salinas CA, Tusié-Luna MT. Contribution of Chromosome 1q21-q23 to Familial Combined Hyperlipidemia in Mexican Families. Ann Hum Genet 2004; 68:419-27. [PMID: 15469419 DOI: 10.1046/j.1529-8817.2003.00116.x] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Familial combined hyperlipidemia (FCHL) is the most common familial dyslipidemia, with a prevalence of 1-2% in the general population. A major locus for FCHL has been mapped to chromosome 1q21-q23 in Finnish, Chinese, German and US families. We studied seven extended Mexican families with 153 members, including 64 affected subjects. A total of 11 markers were genotyped, including D1S104 which has been linked to FCHL in other studies. Two point linkage analysis for the FCHL phenotype, and for the elevated triglyceride (TG) trait, allowing for heterogeneity, gave a maximum HLOD of 1.67 (alpha = 0.49) and 1.93 (alpha = 0.43) at D1S2768 (2.69 cM proximal to D1S104) respectively. Heterogeneity and non-parametric (NPL) multipoint analyses for the FCHL phenotype and the TG trait showed maximum HLODs of 1.27 (alpha = 0.46) and 1.64 (alpha = 0.38), and NPLs of 4.00 (P = 0.0001) and 3.68 (P = 0.0003) near D1S2768, respectively. In addition, analysis of four candidate genes putatively involved in the expression of FCHL showed no evidence of linkage for the LCAT gene or the APOA1/C3/A4/A5 gene cluster. However, we cannot exclude the participation of these genes, or the LIPC and LPL genes, as minor susceptibility loci in the expression of FCHL, or the TG or elevated total cholesterol (TC) traits in our families. In conclusion, our data confirm the involvement of a major susceptibility locus on chromosome 1q21-q23 in FCHL Mexican families, consistent with findings in other populations.
Collapse
Affiliation(s)
- A Huertas-Vázquez
- Unidad de Biología Molecular y Medicina Genómica del Instituto de Investigaciones Biomédicas de la Universidad Nacional Autónoma de México y del Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City
| | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Cardona F, Tinahones FJ, Collantes E, Escudero A, García-Fuentes E, Soriguer FJ. Contribution of polymorphisms in the apolipoprotein AI-CIII-AIV cluster to hyperlipidaemia in patients with gout. Ann Rheum Dis 2004; 64:85-8. [PMID: 15115711 PMCID: PMC1755175 DOI: 10.1136/ard.2003.019695] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BACKGROUND Studies have shown that hyperuricaemia is independently related to the insulin resistance syndrome and that polymorphisms of the apolipoprotein AI-CIII-AIV cluster are also related to insulin resistance. OBJECTIVE To study the prevalence of polymorphisms of the apolipoprotein AI-CIII-AIV cluster in persons with gout and to determine whether these polymorphisms contribute to the pathophysiology of gout or to altered lipid concentrations. METHODS Plasma cholesterol, triglycerides, uric acid, VLDL, LDL, IDL, and HDL triglycerides, cholesterol, and the renal excretion of uric acid were measured in 68 patients with gout with gout and 165 healthy subjects. Polymorphisms were studied by amplification and RFLP in all subjects, using XmnI and MspI in the apolipoprotein AI gene and SstI in the apolipoprotein CIII gene. RESULTS The A allele at position -75 bp in the apolipoprotein AI gene was more common in patients with gout than in controls (p = 0.01). Levels of cholesterol, triglycerides, uric acid, basal glycaemia, and HDL cholesterol were higher in the patients (p<0.001). In the patients there was also an interaction between mutations at the two polymorphic loci studied in the apolipoprotein AI gene (p = 0.04). An absence of the mutation at position -75 bp of the apolipoprotein AI gene resulted in increased plasma triglyceride levels. CONCLUSIONS Gouty patients have an altered allelic distribution in the apolipoprotein AI-CIII-AIV cluster, which could lead to changes in levels of lipoproteins. This is not caused by a single mutation but rather by a combination of different mutations.
Collapse
Affiliation(s)
- F Cardona
- Servicio de Endocrinología y Nutrición, Complejo Hospitalario Universitario Carlos Haya, Malaga, Spain.
| | | | | | | | | | | |
Collapse
|
26
|
Fullerton SM, Buchanan AV, Sonpar VA, Taylor SL, Smith JD, Carlson CS, Salomaa V, Stengård JH, Boerwinkle E, Clark AG, Nickerson DA, Weiss KM. The effects of scale: variation in the APOA1/C3/A4/A5 gene cluster. Hum Genet 2004; 115:36-56. [PMID: 15108119 DOI: 10.1007/s00439-004-1106-x] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2003] [Accepted: 02/16/2004] [Indexed: 01/08/2023]
Abstract
While there is considerable appeal to the idea of selecting a few SNPs to represent all, or much, of the DNA sequence variability in a local chromosomal region, it is also important to quantify what detail is lost in adopting such an approach. To address this issue, we compared high- and low-resolution depictions of sequence diversity for the same genomic region, the APOA1/C3/A4/A5 gene cluster on chromosome 11. First, extensive re-sequencing identified all nucleotide and sequence haplotype variation of the linked apolipoprotein genes in 72 individuals from three populations: African-Americans from Jackson, Miss., Europeans from North Karelia, Finland, and European-Americans from Rochester, Minn. We identified 124 SNPs in 17.7 kb and significant differences in variation among genes. APOC3 gene diversity was particularly distinctive at high resolution, showing large allele frequency differences ( F(ST) values >0.250) between Jackson and the other two samples, and divergent population-specific haplotype lineages. Next, we selected haplotype-tagging SNPs (htSNPs) for each gene, at a density of approximately one SNP per kb, using an algorithm suggested by Stram et al. (2003). The 17 htSNPs identified were then used to reconstruct low-resolution haplotypes, from which inferences about the structure of variation were also drawn. This comparison showed that while the htSNPs successfully tagged common haplotype variation, they also left much underlying sequence diversity undetected and failed, in some cases, to co-classify groups of closely related haplotypes. The implications of these findings for other haplotype-based descriptions of human variation are discussed.
Collapse
Affiliation(s)
- Stephanie M Fullerton
- Department of Anthropology, Penn State University, 409 Carpenter Bldg., University Park, PA 16802, USA.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Verseyden C, Meijssen S, van Dijk H, Jansen H, Castro Cabezas M. Effects of atorvastatin on fasting and postprandial complement component 3 response in familial combined hyperlipidemia. J Lipid Res 2003; 44:2100-8. [PMID: 12923226 DOI: 10.1194/jlr.m300201-jlr200] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
VLDL overproduction by enhanced hepatic FFA flux is a major characteristic of familial combined hyperlipidemia (FCHL). The postprandial complement component 3 (C3) response has been associated with impaired postprandial FFA metabolism in FCHL. We investigated the effects of 16 weeks of treatment with atorvastatin on postprandial C3 and lipid changes in 12 FCHL patients. Atorvastatin significantly lowered fasting plasma C3 and triglyceride (TG) in FCHL. Fasting TG and insulin sensitivity were the best predictors of fasting and postprandial C3. Postprandial triglyceridemia and C3 response, estimated as area under the curve (AUC), were significantly lowered by atorvastatin by 19% and 12%, respectively, albeit still elevated, compared with 10 matched controls. Postprandial FFA-AUC and postheparin plasma lipolytic activities remained unchanged after atorvastatin, suggesting no major effect on lipolysis. After atorvastatin, postprandial hydroxybutyric acid-AUC, which was elevated in untreated FCHL patients, was decreased, reaching values similar to those in controls. The present data show reduction of postprandial hepatic FFA flux in FCHL by atorvastatin, providing an additional mechanistic explanation for the reduction of VLDL secretion reported previously for atorvastatin. This was accompanied by a decrease in fasting plasma C3 concentrations and a blunted postprandial C3 response to an acute oral fat load.
Collapse
Affiliation(s)
- C Verseyden
- Department of Vascular Medicine, University Medical Center Utrecht, Utrecht, The Netherlands
| | | | | | | | | |
Collapse
|
28
|
Eichenbaum-Voline S, Olivier M, Jones EL, Naoumova RP, Jones B, Gau B, Patel HN, Seed M, Betteridge DJ, Galton DJ, Rubin EM, Scott J, Shoulders CC, Pennacchio LA. Linkage and association between distinct variants of the APOA1/C3/A4/A5 gene cluster and familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 2003; 24:167-74. [PMID: 14551155 PMCID: PMC2773540 DOI: 10.1161/01.atv.0000099881.83261.d4] [Citation(s) in RCA: 83] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
OBJECTIVE Combined hyperlipidemia is a common disorder, characterized by a highly atherogenic lipoprotein profile and a substantially increased risk of coronary heart disease. The purpose of this study was to establish whether variations of apolipoprotein A5 (APOA5), a newly discovered gene of lipid metabolism located 30 kbp downstream of the APOA1/C3/A4 gene cluster, contributes to the transmission of familial combined hyperlipidemia (FCHL). METHODS AND RESULTS We performed linkage and association tests on 128 families. Two independent alleles, APOA5c.56G and APOC3c.386G, of the APOA1/C3/A4/A5 gene cluster were overtransmitted in FCHL (P=0.004 and 0.007, respectively). This was paired with reduced transmission of the common APOA1/C3/A4/A5 haplotype (frequency 0.4461) to affected subjects (P=0.012). The APOA5c.56G genotype accounted for 7.3% to 13.8% of the variance in plasma triglyceride levels in probands (P<0.004). The APOC3c.386G genotypes accounted for 4.4% to 5.1% of the variance in triglyceride levels in FCHL spouses (P<0.007), suggesting that this allele marks a FCHL quantitative trait as well as representing a susceptibility locus for the condition. CONCLUSIONS A combined linkage and association analysis establishes that variation at the APOA1/C3/A4/A5 gene cluster contributes to FCHL transmission in a substantial proportion of northern European families.
Collapse
Affiliation(s)
- Sophie Eichenbaum-Voline
- Genomic and Molecular Medicine Group, Medical Research Council Clinical Sciences Centre, Hammersmith Hospital
| | - Michael Olivier
- Human and Molecular Genetics Centre, Medical College of Wisconsin, Milwaukee, Wisc
| | - Emma L. Jones
- Genomic and Molecular Medicine Group, Medical Research Council Clinical Sciences Centre, Hammersmith Hospital
| | - Rossitza P. Naoumova
- Genomic and Molecular Medicine Group, Medical Research Council Clinical Sciences Centre, Hammersmith Hospital
| | - Bethan Jones
- Genomic and Molecular Medicine Group, Medical Research Council Clinical Sciences Centre, Hammersmith Hospital
| | - Brian Gau
- Human and Molecular Genetics Centre, Medical College of Wisconsin, Milwaukee, Wisc
| | - Hetal N. Patel
- Genomic and Molecular Medicine Group, Medical Research Council Clinical Sciences Centre, Hammersmith Hospital
| | - Mary Seed
- Department of Cardiovascular Medicine, Charing Cross Hospital
| | - D. John Betteridge
- Department of Medicine, Royal Free and University College Medical School, University College London
| | - David J. Galton
- Department of Metabolism and Genetics, St Bartholomew’s Hospital, London, UK
| | - Edward M. Rubin
- Genome Sciences Department, Lawerence Berkeley National Laboratory, Berkeley, Calif
- Joint Genome Institute, Department of Energy, Walnut Creek, Calif
| | - James Scott
- Genomic and Molecular Medicine Group, Medical Research Council Clinical Sciences Centre, Hammersmith Hospital
- Genetics and Genomics Research Institute, Imperial College London
| | - Carol C. Shoulders
- Genomic and Molecular Medicine Group, Medical Research Council Clinical Sciences Centre, Hammersmith Hospital
| | - Len A. Pennacchio
- Genome Sciences Department, Lawerence Berkeley National Laboratory, Berkeley, Calif
- Joint Genome Institute, Department of Energy, Walnut Creek, Calif
| |
Collapse
|
29
|
Chhabra S, Agarwal DP, Vasisht S, Luthra K, Narang R, Manchanda SC, Srivastava LM, Das N. Study of apolipoproteinc3 Sstl polymorphism in healthy volunteers from Northern India. Indian J Clin Biochem 2003; 18:34-8. [PMID: 23105390 PMCID: PMC3453890 DOI: 10.1007/bf02867365] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
Several studies including a small case-control (hypertriglyceridemic/normotriglyceridemic individuals) study by us revealed close association between rare S2 allele ofAPOC3 Sstl polymorphism and hypertriglyceridemia. With the understanding that Asian Indians are highly vulnerable to the adverse effects of hypertriglyceridemia, we extended the investigation and studied the frequency distribution of this polymorphism in 216 healthy volunteers from Northern plains of India. We found that more than 50% of the study population had one or two S2 allele. This may suggest that a larger fraction of this population is genetically predisposed to hypertriglyceridemia.
Collapse
Affiliation(s)
- S. Chhabra
- Department of Biochemistry, All India Institute of Medical Sciences, Ansari Nagar, 110029 New Delhi, India
| | - D. P. Agarwal
- Institute of Human Genetics, University of Hamburg, Germany
| | - S. Vasisht
- Department of Cardiology, All India Institute of Medical Sciences, New Delhi, India
| | - K. Luthra
- Department of Biochemistry, All India Institute of Medical Sciences, Ansari Nagar, 110029 New Delhi, India
| | - R. Narang
- Department of Cardiology, All India Institute of Medical Sciences, New Delhi, India
| | - S. C. Manchanda
- Department of Cardiology, All India Institute of Medical Sciences, New Delhi, India
| | - L. M. Srivastava
- Department of Biochemistry, Sir Ganga Ram Hospital, New Delhi, India
| | - N. Das
- Department of Biochemistry, All India Institute of Medical Sciences, Ansari Nagar, 110029 New Delhi, India
| |
Collapse
|
30
|
Aouizerat BE, Kulkarni M, Heilbron D, Drown D, Raskin S, Pullinger CR, Malloy MJ, Kane JP. Genetic analysis of a polymorphism in the human apoA-V gene: effect on plasma lipids. J Lipid Res 2003; 44:1167-73. [PMID: 12671030 DOI: 10.1194/jlr.m200480-jlr200] [Citation(s) in RCA: 100] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Recent discovery and characterization of APOAV suggests a role in metabolism of triglyceride (TG)-rich lipoproteins. Previously, variation at the APOAV locus was shown to modestly influence plasma TGs in normolipidemic samples. The aims of this study were to assess the effects of a polymorphism in APOAV (T-1131C) in terms of its frequency among three dyslipidemic populations and a control population, differences of allele frequency across available ethnic groups, and associations with specific lipoprotein TG and cholesterol compartments. We found a striking elevation in the frequency of the rare allele in a Chinese population (P = 0.0002) compared with Hispanic and European populations. The rare allele of the polymorphism was associated with elevated plasma TG (P = 0.012), VLDL cholesterol (P = 0.0007), and VLDL TG (P = 0.012), LDL TG (P = 0.003), and HDL TG (P = 0.016). Linear regression models predict that possession of the rare allele elevates plasma TG by 21 mg/dl (P = 0.009) and VLDL cholesterol by 8 mg/dl (P = 0.0001), and reduces HDL cholesterol by 2 mg/dl (P = 0.017). The association of the polymorphism with altered lipoprotein profiles was observed in combined hyperlipidemia, hypoalphalipoproteinemia, and hyperalphalipoproteinemia, and in controls. These findings indicate that APOAV is an important determinant of plasma TG and lipoprotein cholesterol, and is potentially a risk factor for cardiovascular disease.
Collapse
Affiliation(s)
- Bradley E Aouizerat
- Department of Physiological Nursing, University of California San Francisco, San Francisco, CA 94143, USA.
| | | | | | | | | | | | | | | |
Collapse
|
31
|
Pajukanta P, Allayee H, Krass KL, Kuraishy A, Soro A, Lilja HE, Mar R, Taskinen MR, Nuotio I, Laakso M, Rotter JI, de Bruin TWA, Cantor RM, Lusis AJ, Peltonen L. Combined analysis of genome scans of dutch and finnish families reveals a susceptibility locus for high-density lipoprotein cholesterol on chromosome 16q. Am J Hum Genet 2003; 72:903-17. [PMID: 12638083 PMCID: PMC1180353 DOI: 10.1086/374177] [Citation(s) in RCA: 81] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2002] [Accepted: 01/08/2003] [Indexed: 12/31/2022] Open
Abstract
Several genomewide screens have been performed to identify novel loci predisposing to unfavorable serum lipid levels and coronary heart disease (CHD). We hypothesized that the accumulating data of these screens in different study populations could be combined to verify which of the identified loci truly harbor susceptibility genes. The power of this strategy has recently been demonstrated with other complex diseases, such as inflammatory bowel disease and asthma. We assessed the largely unknown genetic background of CHD by investigating the most common dyslipidemia predisposing to CHD, familial combined hyperlipidemia (FCHL), affecting 1%-2% of Western populations and 10%-20% of families with premature CHD. To be able to perform a combined data analysis, we unified the diagnostic criteria for FCHL and its component traits and combined the data from two genomewide scans performed in two populations, the Finns and the Dutch. As a result of our pooled data analysis, we identified three chromosomal regions, on chromosomes 2p25.1, 9p23, and 16q24.1, exceeding the statistical significance level of a LOD score >2.0. The 2p25.1 region was detected for the FCHL trait, and the 9p23 and 16q24.1 regions were detected for the low high-density lipoprotein cholesterol (HDL-C) trait. In addition, the previously recognized 1q21 region also obtained additional support in the other study sample, when the triglyceride trait was used. Analysis of the 16q24.1 region resulted in a statistically significant LOD score of 3.6 when the data from Finnish families with low HDL-C were included in the analysis. To search for the underlying gene in the 16q24.1 region, we investigated a novel functional and positional candidate gene, helix/forkhead transcription factor (FOXC2), by sequencing and by genotyping of two single-nucleotide polymorphisms in the families.
Collapse
Affiliation(s)
- Päivi Pajukanta
- Departments of Human Genetics, Microbiology and Molecular Genetics, Medicine, and Pediatrics and Molecular Biology Institute, David Geffen School of Medicine at the University of California–Los Angeles, and Division of Medical Genetics, Steven Spielberg Pediatric Research Center and Cedars-Sinai Research Institute, Los Angeles; Department of Medicine, Helsinki University Central Hospital, and Department of Molecular Medicine, National Public Health Institute, and Department of Medical Genetics, University of Helsinki, Helsinki; Department of Medicine, Turku University Central Hospital, Turku, Finland; Department of Medicine, Kuopio University Central Hospital, Kuopio, Finland; and Department of Medicine and the Cardiovascular Research Institute Maastricht, Academic Hospital, Maastricht, the Netherlands
| | - Hooman Allayee
- Departments of Human Genetics, Microbiology and Molecular Genetics, Medicine, and Pediatrics and Molecular Biology Institute, David Geffen School of Medicine at the University of California–Los Angeles, and Division of Medical Genetics, Steven Spielberg Pediatric Research Center and Cedars-Sinai Research Institute, Los Angeles; Department of Medicine, Helsinki University Central Hospital, and Department of Molecular Medicine, National Public Health Institute, and Department of Medical Genetics, University of Helsinki, Helsinki; Department of Medicine, Turku University Central Hospital, Turku, Finland; Department of Medicine, Kuopio University Central Hospital, Kuopio, Finland; and Department of Medicine and the Cardiovascular Research Institute Maastricht, Academic Hospital, Maastricht, the Netherlands
| | - Kelly L. Krass
- Departments of Human Genetics, Microbiology and Molecular Genetics, Medicine, and Pediatrics and Molecular Biology Institute, David Geffen School of Medicine at the University of California–Los Angeles, and Division of Medical Genetics, Steven Spielberg Pediatric Research Center and Cedars-Sinai Research Institute, Los Angeles; Department of Medicine, Helsinki University Central Hospital, and Department of Molecular Medicine, National Public Health Institute, and Department of Medical Genetics, University of Helsinki, Helsinki; Department of Medicine, Turku University Central Hospital, Turku, Finland; Department of Medicine, Kuopio University Central Hospital, Kuopio, Finland; and Department of Medicine and the Cardiovascular Research Institute Maastricht, Academic Hospital, Maastricht, the Netherlands
| | - Ali Kuraishy
- Departments of Human Genetics, Microbiology and Molecular Genetics, Medicine, and Pediatrics and Molecular Biology Institute, David Geffen School of Medicine at the University of California–Los Angeles, and Division of Medical Genetics, Steven Spielberg Pediatric Research Center and Cedars-Sinai Research Institute, Los Angeles; Department of Medicine, Helsinki University Central Hospital, and Department of Molecular Medicine, National Public Health Institute, and Department of Medical Genetics, University of Helsinki, Helsinki; Department of Medicine, Turku University Central Hospital, Turku, Finland; Department of Medicine, Kuopio University Central Hospital, Kuopio, Finland; and Department of Medicine and the Cardiovascular Research Institute Maastricht, Academic Hospital, Maastricht, the Netherlands
| | - Aino Soro
- Departments of Human Genetics, Microbiology and Molecular Genetics, Medicine, and Pediatrics and Molecular Biology Institute, David Geffen School of Medicine at the University of California–Los Angeles, and Division of Medical Genetics, Steven Spielberg Pediatric Research Center and Cedars-Sinai Research Institute, Los Angeles; Department of Medicine, Helsinki University Central Hospital, and Department of Molecular Medicine, National Public Health Institute, and Department of Medical Genetics, University of Helsinki, Helsinki; Department of Medicine, Turku University Central Hospital, Turku, Finland; Department of Medicine, Kuopio University Central Hospital, Kuopio, Finland; and Department of Medicine and the Cardiovascular Research Institute Maastricht, Academic Hospital, Maastricht, the Netherlands
| | - Heidi E. Lilja
- Departments of Human Genetics, Microbiology and Molecular Genetics, Medicine, and Pediatrics and Molecular Biology Institute, David Geffen School of Medicine at the University of California–Los Angeles, and Division of Medical Genetics, Steven Spielberg Pediatric Research Center and Cedars-Sinai Research Institute, Los Angeles; Department of Medicine, Helsinki University Central Hospital, and Department of Molecular Medicine, National Public Health Institute, and Department of Medical Genetics, University of Helsinki, Helsinki; Department of Medicine, Turku University Central Hospital, Turku, Finland; Department of Medicine, Kuopio University Central Hospital, Kuopio, Finland; and Department of Medicine and the Cardiovascular Research Institute Maastricht, Academic Hospital, Maastricht, the Netherlands
| | - Rebecca Mar
- Departments of Human Genetics, Microbiology and Molecular Genetics, Medicine, and Pediatrics and Molecular Biology Institute, David Geffen School of Medicine at the University of California–Los Angeles, and Division of Medical Genetics, Steven Spielberg Pediatric Research Center and Cedars-Sinai Research Institute, Los Angeles; Department of Medicine, Helsinki University Central Hospital, and Department of Molecular Medicine, National Public Health Institute, and Department of Medical Genetics, University of Helsinki, Helsinki; Department of Medicine, Turku University Central Hospital, Turku, Finland; Department of Medicine, Kuopio University Central Hospital, Kuopio, Finland; and Department of Medicine and the Cardiovascular Research Institute Maastricht, Academic Hospital, Maastricht, the Netherlands
| | - Marja-Riitta Taskinen
- Departments of Human Genetics, Microbiology and Molecular Genetics, Medicine, and Pediatrics and Molecular Biology Institute, David Geffen School of Medicine at the University of California–Los Angeles, and Division of Medical Genetics, Steven Spielberg Pediatric Research Center and Cedars-Sinai Research Institute, Los Angeles; Department of Medicine, Helsinki University Central Hospital, and Department of Molecular Medicine, National Public Health Institute, and Department of Medical Genetics, University of Helsinki, Helsinki; Department of Medicine, Turku University Central Hospital, Turku, Finland; Department of Medicine, Kuopio University Central Hospital, Kuopio, Finland; and Department of Medicine and the Cardiovascular Research Institute Maastricht, Academic Hospital, Maastricht, the Netherlands
| | - Ilpo Nuotio
- Departments of Human Genetics, Microbiology and Molecular Genetics, Medicine, and Pediatrics and Molecular Biology Institute, David Geffen School of Medicine at the University of California–Los Angeles, and Division of Medical Genetics, Steven Spielberg Pediatric Research Center and Cedars-Sinai Research Institute, Los Angeles; Department of Medicine, Helsinki University Central Hospital, and Department of Molecular Medicine, National Public Health Institute, and Department of Medical Genetics, University of Helsinki, Helsinki; Department of Medicine, Turku University Central Hospital, Turku, Finland; Department of Medicine, Kuopio University Central Hospital, Kuopio, Finland; and Department of Medicine and the Cardiovascular Research Institute Maastricht, Academic Hospital, Maastricht, the Netherlands
| | - Markku Laakso
- Departments of Human Genetics, Microbiology and Molecular Genetics, Medicine, and Pediatrics and Molecular Biology Institute, David Geffen School of Medicine at the University of California–Los Angeles, and Division of Medical Genetics, Steven Spielberg Pediatric Research Center and Cedars-Sinai Research Institute, Los Angeles; Department of Medicine, Helsinki University Central Hospital, and Department of Molecular Medicine, National Public Health Institute, and Department of Medical Genetics, University of Helsinki, Helsinki; Department of Medicine, Turku University Central Hospital, Turku, Finland; Department of Medicine, Kuopio University Central Hospital, Kuopio, Finland; and Department of Medicine and the Cardiovascular Research Institute Maastricht, Academic Hospital, Maastricht, the Netherlands
| | - Jerome I. Rotter
- Departments of Human Genetics, Microbiology and Molecular Genetics, Medicine, and Pediatrics and Molecular Biology Institute, David Geffen School of Medicine at the University of California–Los Angeles, and Division of Medical Genetics, Steven Spielberg Pediatric Research Center and Cedars-Sinai Research Institute, Los Angeles; Department of Medicine, Helsinki University Central Hospital, and Department of Molecular Medicine, National Public Health Institute, and Department of Medical Genetics, University of Helsinki, Helsinki; Department of Medicine, Turku University Central Hospital, Turku, Finland; Department of Medicine, Kuopio University Central Hospital, Kuopio, Finland; and Department of Medicine and the Cardiovascular Research Institute Maastricht, Academic Hospital, Maastricht, the Netherlands
| | - Tjerk W. A. de Bruin
- Departments of Human Genetics, Microbiology and Molecular Genetics, Medicine, and Pediatrics and Molecular Biology Institute, David Geffen School of Medicine at the University of California–Los Angeles, and Division of Medical Genetics, Steven Spielberg Pediatric Research Center and Cedars-Sinai Research Institute, Los Angeles; Department of Medicine, Helsinki University Central Hospital, and Department of Molecular Medicine, National Public Health Institute, and Department of Medical Genetics, University of Helsinki, Helsinki; Department of Medicine, Turku University Central Hospital, Turku, Finland; Department of Medicine, Kuopio University Central Hospital, Kuopio, Finland; and Department of Medicine and the Cardiovascular Research Institute Maastricht, Academic Hospital, Maastricht, the Netherlands
| | - Rita M. Cantor
- Departments of Human Genetics, Microbiology and Molecular Genetics, Medicine, and Pediatrics and Molecular Biology Institute, David Geffen School of Medicine at the University of California–Los Angeles, and Division of Medical Genetics, Steven Spielberg Pediatric Research Center and Cedars-Sinai Research Institute, Los Angeles; Department of Medicine, Helsinki University Central Hospital, and Department of Molecular Medicine, National Public Health Institute, and Department of Medical Genetics, University of Helsinki, Helsinki; Department of Medicine, Turku University Central Hospital, Turku, Finland; Department of Medicine, Kuopio University Central Hospital, Kuopio, Finland; and Department of Medicine and the Cardiovascular Research Institute Maastricht, Academic Hospital, Maastricht, the Netherlands
| | - Aldons J. Lusis
- Departments of Human Genetics, Microbiology and Molecular Genetics, Medicine, and Pediatrics and Molecular Biology Institute, David Geffen School of Medicine at the University of California–Los Angeles, and Division of Medical Genetics, Steven Spielberg Pediatric Research Center and Cedars-Sinai Research Institute, Los Angeles; Department of Medicine, Helsinki University Central Hospital, and Department of Molecular Medicine, National Public Health Institute, and Department of Medical Genetics, University of Helsinki, Helsinki; Department of Medicine, Turku University Central Hospital, Turku, Finland; Department of Medicine, Kuopio University Central Hospital, Kuopio, Finland; and Department of Medicine and the Cardiovascular Research Institute Maastricht, Academic Hospital, Maastricht, the Netherlands
| | - Leena Peltonen
- Departments of Human Genetics, Microbiology and Molecular Genetics, Medicine, and Pediatrics and Molecular Biology Institute, David Geffen School of Medicine at the University of California–Los Angeles, and Division of Medical Genetics, Steven Spielberg Pediatric Research Center and Cedars-Sinai Research Institute, Los Angeles; Department of Medicine, Helsinki University Central Hospital, and Department of Molecular Medicine, National Public Health Institute, and Department of Medical Genetics, University of Helsinki, Helsinki; Department of Medicine, Turku University Central Hospital, Turku, Finland; Department of Medicine, Kuopio University Central Hospital, Kuopio, Finland; and Department of Medicine and the Cardiovascular Research Institute Maastricht, Academic Hospital, Maastricht, the Netherlands
| |
Collapse
|
32
|
Tilly P, Sass C, Vincent-Viry M, Aguillon D, Siest G, Visvikis S. Biological and genetic determinants of serum apoC-III concentration: reference limits from the Stanislas Cohort. J Lipid Res 2003; 44:430-6. [PMID: 12576526 DOI: 10.1194/jlr.m200006-jlr200] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Apolipoprotein C-III (apoC-III) is involved in triglycerides metabolism, and is therefore important for the pathogenesis of coronary heart diseases. However, to our knowledge serum apoC-III variation factors and reference limits have never been determined, so the aim of this study was to establish them and facilitate clinical usefulness. We measured serum apoC-III concentration of apparently healthy subjects of the Stanislas Cohort by an immunoturbidimetric method. Genetic polymorphisms within the APOC3, APOE, APOAIV, and LPL genes were determined by a multiplex PCR. Serum apoC-III concentration varied from 28.2 mg/l to 225.8 mg/l in the overall sample and between subjects variability was about 30%. Factors influencing apoC-III concentration were age, BMI in adult men, alcohol consumption in adults, oral contraceptive intake in women, the post-pubescent status in boys. The APOC3 1100T allele in adult men and the APOC3 -455C allele in boys were associated with increased apoC-III concentration. The APOA4 360His allele was associated with decreased apoC-III concentration in women. We also established reference limits of serum apoC-III concentration according to age and gender.
Collapse
Affiliation(s)
- Peggy Tilly
- Institut National de Santé et de Recherche Médicale U525, Centre de Médecine Préventive, 2 Avenue du Doyen J. Parisot, F54500 Vandoeuvre-Lès-Nancy, France
| | | | | | | | | | | |
Collapse
|
33
|
Eurlings PMH, van der Kallen CJH, Geurts JMW, Flavell DM, de Bruin TWA. Identification of the PPARA locus on chromosome 22q13.3 as a modifier gene in familial combined hyperlipidemia. Mol Genet Metab 2002; 77:274-81. [PMID: 12468272 DOI: 10.1016/s1096-7192(02)00174-9] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Familial combined hyperlipidemia (FCHL) is a common genetic lipid disorder that is present in 10% of patients with premature coronary artery disease (CAD). It was the objective of the present study to evaluate the possible involvement of the PPARA locus in the pathophysiology of FCHL. Mutation detection analyses of the six coding PPARA exons resulted in the identification of four novel variants, [C/T] intron 3, S234G, [G/A] intron 5, and [C/A] 3(') UTR in three FCHL probands, whereas no novel variants were identified in spouses. In a case-control study, markers D22S275 and D22S928 were shown not to be associated with FCHL. However, D22S928, mapped within 1Mb of the PPARA gene, was shown to have a modifying effect on plasma apoCIII concentrations (P=0.011) and the combined hyperlipidemic FCHL phenotype (P=0.038). In addition two PPARA polymorphisms in intron 2 and 7 were studied, but these were not associated with FCHL. The frequency of the L162V variant was less in FCHL probands (1.98%) compared to that in spouses (4.84%). These results clearly demonstrate the genetically complex nature of FCHL and identify the PPARA gene as a modifier of the FCHL phenotype.
Collapse
Affiliation(s)
- Petra M H Eurlings
- Department of Internal Medicine, Laboratory of Molecular Metabolism and Endocrinology, Cardiovascular Research Institute Maastricht, University of Maastricht, PO Box 616, Maastricht, NL-6200 MD, The Netherlands.
| | | | | | | | | |
Collapse
|
34
|
van Greevenbroek MMJ, Vermeulen VMMJ, de Bruin TWA. Familial combined hyperlipidemia plasma stimulates protein secretion by HepG2 cells: identification of fibronectin in the differential secretion proteome. J Lipid Res 2002; 43:1846-54. [PMID: 12401883 DOI: 10.1194/jlr.m100441-jlr200] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
The aim of this study was to evaluate whether soluble factors in plasma of familial combined hyperlipidemia (FCHL) patients affect hepatic protein secretion. Cultured human hepatocytes, i.e., HepG2 cells, were incubated with fasting plasma (20%, v/v, in DMEM) from untreated FCHL patients or normolipidemic controls. Overall protein secretion was 10-15% higher after incubation with FCHL plasma. This was specifically caused by an increase in four secreted proteins, with estimated sizes of 240, 180, 120, and <40 kD (P < 0.001, P < 0.006, P < 0.002, P < 0.02, respectively). The 240 kD protein in the secretion proteome was identified as fibronectin by mass spectrometry. Plasma fibronectin concentrations were elevated in FCHL patients, confirming biological relevance of these data. Overall protein secretion by HepG2 cells correlated with concentrations of triglycerides (r = 0.61, P < 0.001) in the applied plasma samples. VLDL+IDL isolated from FCHL patients, induced a higher protein secretion than lipoproteins isolated from controls (P < 0.001). Remarkably, secretion of apoB, the structural protein of VLDL, was stimulated to a similar extent by FCHL and control plasma. FCHL plasma did not induce excess secretion of apoB by HepG2 cells compared with control plasma. FCHL plasma did stimulate secretion of several distinct hepatic proteins, among which fibronectin was identified.
Collapse
|
35
|
Kwiterovich PO. Clinical relevance of the biochemical, metabolic, and genetic factors that influence low-density lipoprotein heterogeneity. Am J Cardiol 2002; 90:30i-47i. [PMID: 12419479 DOI: 10.1016/s0002-9149(02)02749-2] [Citation(s) in RCA: 128] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Traditional risk factors for coronary artery disease (CAD) predict about 50% of the risk of developing CAD. The Adult Treatment Panel (ATP) III has defined emerging risk factors for CAD, including small, dense low-density lipoprotein (LDL). Small, dense LDL is often accompanied by increased triglycerides (TGs) and low high-density lipoprotein (HDL). An increased number of small, dense LDL particles is often missed when the LDL cholesterol level is normal or borderline elevated. Small, dense LDL particles are present in families with premature CAD and hyperapobetalipoproteinemia, familial combined hyperlipidemia, LDL subclass pattern B, familial dyslipidemic hypertension, and syndrome X. The metabolic syndrome, as defined by ATP III, incorporates a number of the components of these syndromes, including insulin resistance and intra-abdominal fat. Subclinical inflammation and elevated procoagulants also appear to be part of this atherogenic syndrome. Overproduction of very low-density lipoproteins (VLDLs) by the liver and increased secretion of large, apolipoprotein (apo) B-100-containing VLDL is the primary metabolic characteristic of most of these patients. The TG in VLDL is hydrolyzed by lipoprotein lipase (LPL) which produces intermediate-density lipoprotein. The TG in intermediate-density lipoprotein is hydrolyzed further, resulting in the generation of LDL. The cholesterol esters in LDL are exchanged for TG in VLDL by the cholesterol ester tranfer proteins, followed by hydrolysis of TG in LDL by hepatic lipase which produces small, dense LDL. Cholesterol ester transfer protein mediates a similar lipid exchange between VLDL and HDL, producing a cholesterol ester-poor HDL. In adipocytes, reduced fatty acid trapping and retention by adipose tissue may result from a primary defect in the incorporation of free fatty acids into TGs. Alternatively, insulin resistance may promote reduced retention of free fatty acids by adipocytes. Both these abnormalities lead to increased levels of free fatty acids in plasma, increased flux of free fatty acids back to the liver, enhanced production of TGs, decreased proteolysis of apo B-100, and increased VLDL production. Decreased removal of postprandial TGs often accompanies these metabolic abnormalities. Genes regulating the expression of the major players in this metabolic cascade, such as LPL, cholesterol ester transfer protein, and hepatic lipase, can modulate the expression of small, dense LDL but these are not the major defects. New candidates for major gene effects have been identified on chromosome 1. Regardless of their fundamental causes, small, dense LDL (compared with normal LDL) particles have a prolonged residence time in plasma, are more susceptible to oxidation because of decreased interaction with the LDL receptor, and enter the arterial wall more easily, where they are retained more readily. Small, dense LDL promotes endothelial dysfunction and enhanced production of procoagulants by endothelial cells. Both in animal models of atherosclerosis and in most human epidemiologic studies and clinical trials, small, dense LDL (particularly when present in increased numbers) appears more atherogenic than normal LDL. Treatment of patients with small, dense LDL particles (particularly when accompanied by low HDL and hypertriglyceridemia) often requires the use of combined lipid-altering drugs to decrease the number of particles and to convert them to larger, more buoyant LDL. The next critical step in further reduction of CAD will be the correct diagnosis and treatment of patients with small, dense LDL and the dyslipidemia that accompanies it.
Collapse
Affiliation(s)
- Peter O Kwiterovich
- Lipid Research Atherosclerosis Division, Departments of Pediatrics and Medicine, the Johns Hopkins University School of Medicine, University Lipid Clinic, Baltimore, Maryland 21205, USA.
| |
Collapse
|
36
|
van der Kallen CJH, Voors-Pette C, Bouwman FG, Keizer HA, Lu JY, van de Hulst RRWJ, Bianchi R, Janssen MJ, Keulen ETP, Boeckx WD, Rotter JI, de Bruin TWA. Evidence of insulin resistant lipid metabolism in adipose tissue in familial combined hyperlipidemia, but not type 2 diabetes mellitus. Atherosclerosis 2002; 164:337-46. [PMID: 12204806 DOI: 10.1016/s0021-9150(02)00109-0] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
In patients with familial combined hyperlipidemia (FCHL) and type 2 diabetes (DM2) organ-specific differences in insulin resistance may exist. In FCHL and DM2 in vivo insulin mediated muscle glucose uptake and inhibition of lipolysis were studied by euglycemic hyperinsulinemic clamp. Insulin mediated glucose uptake was impaired to the same extent in both FCHL and DM2. Only FCHL subjects showed no reduction in plasma glycerol concentrations during insulin infusion and incomplete suppression of plasma free fatty acid (FFA) concentrations combined. This finding indicated that insulin-induced suppression of lipolysis, or glycerol/FFA utilization, or both, were impaired in FCHL, in contrast to DM2 or control subjects. To analyze these possibilities in more detail, control, FCHL, and DM2 adipocytes were studied in vitro. In contrast to adipocytes from DM2 or control subjects, no reduction in medium FFA concentration was detected with FCHL adipocytes after incubation with insulin. This finding indicated impaired intracellular FFA utilization, most likely impaired FFA re-esterification. Genetic linkage analysis in 18 Dutch families with FCHL revealed no evidence for involvement of LIPE, the hormone sensitive lipase gene, indicating that genetic variation in adipocyte lipolysis by LIPE is not the key defect in FCHL. In conclusion, FCHL as well as DM2 subjects exhibited in vivo insulin resistance to glucose disposal, which occurs mainly in muscle. FCHL subjects showed insulin resistant adipose tissue lipid metabolism, in contrast to DM2 and controls. The different pattern of organ-specific insulin resistance in FCHL versus DM2 advances our understanding of differences and similarities in phenotypes between these disorders.
Collapse
Affiliation(s)
- Carla J H van der Kallen
- Department of Medicine, Laboratory of Molecular Endocrinology and Metabolism, Cardiovascular Research Institute Maastricht, University of Maastricht, Maastricht, The Netherlands
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Ribalta J, Figuera L, Fernández-Ballart J, Vilella E, Castro Cabezas M, Masana L, Joven J. Newly Identified Apolipoprotein AV Gene Predisposes to High Plasma Triglycerides in Familial Combined Hyperlipidemia. Clin Chem 2002. [DOI: 10.1093/clinchem/48.9.1597] [Citation(s) in RCA: 96] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Affiliation(s)
| | | | - Joan Fernández-Ballart
- Unitat de Medicina Preventiva i Salut Pública, Institut de Recerca en Ciències de la Salut, Hospital Universitari de Sant Joan, Universitat Rovira i Virgili, 43201 Reus, Spain
| | | | - Manuel Castro Cabezas
- Department of Vascular Medicine, University Medical Center, 3508 GA Utrecht, The Netherlands
| | | | | |
Collapse
|
38
|
Han Z, Heath SC, Shmulewitz D, Li W, Auerbach SB, Blundell ML, Lehner T, Ott J, Stoffel M, Friedman JM, Breslow JL. Candidate genes involved in cardiovascular risk factors by a family-based association study on the island of Kosrae, Federated States of Micronesia. AMERICAN JOURNAL OF MEDICAL GENETICS 2002; 110:234-42. [PMID: 12116231 DOI: 10.1002/ajmg.10445] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Altered plasma levels of lipids and lipoproteins, obesity, hypertension, and diabetes are major risk factors for atherosclerotic cardiovascular disease. To identify genes that affect these traits and disorders, we looked for association between markers in candidate genes (apolipoprotein AII (apo AII), apolipoprotein AI-CIII-AIV gene cluster (apo AI-CIII-AIV), apolipoprotein E (apo E), cholesteryl ester transfer protein (CETP), cholesterol 7alpha-hydroxylase (CYP7a), hepatic lipase (HL), and microsomal triglyceride transfer protein (MTP)) and known risk factors (triglycerides (Tg), total cholesterol (TC), apolipoprotein AI (apo AI), apolipoprotein AII (apo AII), apolipoprotein B (apo B), body mass index (BMI), blood pressure (BP), leptin, and fasting blood sugar (FBS) levels.) A total of 1,102 individuals from the Pacific island of Kosrae were genotyped for the following markers: Apo AII/MspI, Apo CIII/SstI, Apo AI/XmnI, Apo E/HhaI, CETP/TaqIB, CYP7a/BsaI, HL/DraI, and MTP/HhpI. After testing for population stratification, family-based association analysis was carried out. Novel associations found were: 1) the apo AII/MspI with apo AI and BP levels, 2) the CYP7a/BsaI with apo AI and BMI levels. We also confirmed the following associations: 1) the apo AII/MspI with Tg level; 2) the apo CIII/SstI with Tg, TC, and apo B levels; 3) the Apo E/HhaI E2, E3, and E4 alleles with TC, apo AI, and apo B levels; and 4) the CETP/TaqIB with apo AI level. We further confirmed the connection between the apo AII gene and Tg level by a nonparametric linkage analysis. We therefore conclude that many of these candidate genes may play a significant role in susceptibility to heart disease.
Collapse
Affiliation(s)
- Zhihua Han
- Starr Center Human Genetics, Rockefeller University, New York, New York 10021, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Chhabra S, Narang R, Krishnan LR, Vasisht S, Agarwal DP, Srivastava LM, Manchanda SC, Das N. Apolipoprotein C3 SstI polymorphism and triglyceride levels in Asian Indians. BMC Genet 2002; 3:9. [PMID: 12052247 PMCID: PMC116591 DOI: 10.1186/1471-2156-3-9] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2002] [Accepted: 06/06/2002] [Indexed: 01/08/2023] Open
Abstract
BACKGROUND A close association between Sst I polymorphism in the 3' untranslated region of the apolipoproteinC3 (APOC3) gene and levels of plasma triglycerides (TG) had been reported by different investigators. Hypertriglyceridemia(HTG) is a known risk factor for coronary artery disease (CAD) in the context of Asian Indians. We conducted a study on the relationship between APOC3 SstI polymorphism (S1S1, S1S2 and S2S2 genotypes) and plasma TG levels in a group of 139 male healthy volunteers from Northern India. METHODS DNA samples were analyzed by polymerase chain reaction (PCR) followed by SstI digestion. Digested PCR products were run on 3% agarose gel and visualized by ethidium bromide staining. RESULTS Rare S2 allele was highly prevalent in our study population (0.313) as compared to the Caucasians (0.00-0.11). The genotypic distribution was in agreement with Hardy-Weinberg equilibrium. S2 allele was almost two times more prevalent in the HTG group (N = 34) as compared to NTG group (N = 105) (p = 0.001). Multiple logistic regression revealed S1S2 individuals had age-adjusted odds ratio of 2.43 (95%CI = 0.99-6.01, p = 0.054) and S2S2 had 9.9 (95%CI = 2.66-37.29, p = 0.0006) for developing HTG in comparison to S1S1 genotype. CONCLUSIONS Our study shows a significant association between rare S2 allele and HTG in Asian Indians.
Collapse
Affiliation(s)
- S Chhabra
- Departments of Biochemistry, All India Institute of Medical Sciences, New Delhi-110029, India
| | - R Narang
- Department of Cardiology, All India Institute of Medical Sciences, New Delhi-110029, India
| | - LR Krishnan
- Department of Cardiac Biochemistry, All India Institute of Medical Sciences, New Delhi-110029, India
| | - S Vasisht
- Department of Cardiac Biochemistry, All India Institute of Medical Sciences, New Delhi-110029, India
| | - DP Agarwal
- Institute of Human Genetics, University of Hamburg, Germany
| | - LM Srivastava
- Department of Biochemistry, Sir Ganga Ram Hospital, New Delhi-110060, India
| | - SC Manchanda
- Department of Cardiology, All India Institute of Medical Sciences, New Delhi-110029, India
| | - N Das
- Departments of Biochemistry, All India Institute of Medical Sciences, New Delhi-110029, India
| |
Collapse
|
40
|
Meijssen S, van Dijk H, Verseyden C, Erkelens DW, Cabezas MC. Delayed and exaggerated postprandial complement component 3 response in familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 2002; 22:811-6. [PMID: 12006395 DOI: 10.1161/01.atv.0000014079.98335.72] [Citation(s) in RCA: 40] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Very low density lipoprotein overproduction is the major metabolic characteristic in familial combined hyperlipidemia (FCHL). Peripheral handling of free fatty acids (FFAs) in vitro may be impaired in FCHL by decreased action of acylation-stimulating protein (ASP), which is identical to the immunologically inactive complement component 3a (C3adesArg). Because decreased FFA uptake by impaired complement component 3 (C3) response (as the precursor for ASP) may result in enhanced FFA flux to the liver in FCHL, we have evaluated postprandial C3 changes in vivo in FCHL patients. Accordingly, 10 untreated FCHL patients and 10 matched control subjects underwent an oral fat loading test. Fasting plasma C3 and ASP levels were higher in FCHL patients (1.33+/-0.09 g/L and 70.53+/-4.37 mmol/L, respectively) than in control subjects (0.91+/-0.03 g/L and 43.21+/-8.96 mmol/L, respectively; P=0.01 and P<0.05). In control subjects, C3 concentrations increased significantly after 4 hours (to 1.03+/-0.04 g/L). In FCHL, plasma C3 was unchanged after 4 hours. The earliest postprandial C3 rise in FCHL patients occurred after 8 hours (1.64+/-0.12 g/L). The maximal apolipoprotein B-48 concentration was reached after 6 hours in FCHL patients and control subjects. Postprandial FFA and hydroxybutyric acid (as a marker of hepatic FFA oxidation) were significantly higher in FCHL patients than in control subjects, and the early postprandial C3 rise was negatively correlated with the postprandial FFA and hydroxybutyric acid concentrations. The present data suggest an impaired postprandial plasma C3 response in FCHL patients, most likely as a result of a delayed response by C3, as the precursor for the biologically active ASP, acting on FFA metabolism. Therefore, an impaired postprandial C3 response may be associated with impaired peripheral postprandial FFA uptake and, consequently, lead to increased hepatic FFA flux and very low density lipoprotein overproduction.
Collapse
Affiliation(s)
- S Meijssen
- Department of Vascular Medicine, University Medical Center Utrecht, Utrecht, The Netherlands
| | | | | | | | | |
Collapse
|
41
|
Larson IA, Ordovas JM, Barnard JR, Hoffmann MM, Feussner G, Lamon-Fava S, Schaefer EJ. Effects of apolipoprotein A-I genetic variations on plasma apolipoprotein, serum lipoprotein and glucose levels. Clin Genet 2002; 61:176-84. [PMID: 12000358 DOI: 10.1034/j.1399-0004.2002.610302.x] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
The present authors investigated the individual and combined associations of the apolipoprotein (apo) A-I -75 bp and +83 bp polymorphisms with plasma lipid, lipoprotein and apolipoprotein levels in 734 Caucasian men and women. The frequency of the A allele at position -75 bp (G-->A) was 0.14 in women and 0.17 in men. The frequencies for the rare M2 allele at position +83 bp and/or 84 bp (C-->T and G-->A, respectively) were 0.04 and 0.05 in women and men, respectively. In women, the A allele was associated with significantly higher levels of apo B (P = 0.016), total cholesterol (TC) (P = 0.005), low-density lipoprotein cholesterol (LDL-C) (P = 0.018) and TC:high-density lipoprotein (HDL) ratio (P = 0.026) compared to the G/G subjects. In men, no significant associations were detected between the -75 bp polymorphism and any lipid trait examined. The M2 allele for the +83 bp polymorphism was significantly associated in men with higher levels of apo A-I (P = 0.002) and TC (P = 0.046). In women, a significant effect was observed for TC (P = 0.036), with M2+/- subjects having lower levels than M2+/+ subjects. Significant linkage disequilibrium (P = 0.037) between the apo A-I -75 bp and +83 bp polymorphisms was detected. Women carrying both rare alleles (G/A M2+/-) had significantly higher TC:HDL ratios (P = 0.031) compared to the other haplotypes. In men, significant differences were observed for apo A-I (P = 0.021) and TC (P = 0.044), with carriers of the G/G M2+/- haplotype having the highest values compared to other genotype combinations. In conclusion, the -75 bp (G/A) polymorphism appears to have a significant effect on levels of apo B, plasma TC and LDL-C in women, while the +83 bp polymorphism seems to affect the apo A-I levels in men, and the plasma cholesterol levels in both genders.
Collapse
Affiliation(s)
- I A Larson
- Lipid Metabolism Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Tufts University School of Medicine, New England Medical Center, Boston, MA, USA
| | | | | | | | | | | | | |
Collapse
|
42
|
Hegele RA. Monogenic dyslipidemias: window on determinants of plasma lipoprotein metabolism. Am J Hum Genet 2001; 69:1161-77. [PMID: 11704922 PMCID: PMC1235529 DOI: 10.1086/324647] [Citation(s) in RCA: 63] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2001] [Accepted: 09/27/2001] [Indexed: 12/19/2022] Open
Affiliation(s)
- R A Hegele
- John P. Robarts Research Institute, London, Ontario, Canada.
| |
Collapse
|
43
|
Groenendijk M, Cantor RM, Funke H, Dallinga-Thie GM. Two newly identified SNPs in the APO AI-CIII intergenic region are strongly associated with familial combined hyperlipidaemia. Eur J Clin Invest 2001; 31:852-9. [PMID: 11737222 DOI: 10.1046/j.1365-2362.2001.00888.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
BACKGROUND We previously reported linkage and association of the apoAI-CIII-AIV gene region on chromosome 11 with familial combined hyperlipidaemia (FCHL). However, the observed epistasis resulting in an increased susceptibility to FCHL still remains unexplained. We hypothesize that the region between the apo AI and apo CIII genes may harbour functional mutations that might be in linkage disequilibrium with the already identified SstI and MspI polymorphisms, and provide an alternative explanation for the observed relationship. METHODS Using sequence analysis, we identified four new single nucleotide polymorphisms (SNPs) in the apo AI-CIII intergenic region. These four variants, T(3213)C, A(3235)C, T(3287)C and A(5132)C, were studied in 30 FCHL probands, 159 hyperlipidaemic relatives, 327 normolipidaemic relatives, and 218 spouses from the same families in which the original results were obtained. RESULTS The allele frequencies were significantly different between probands and spouses (P < 0.05). Transmission/disequilibrium test (TDT) analyses revealed more frequent transmission of the minor alleles to the affected offspring. The minor genotype was associated with elevated plasma cholesterol and triglyceride levels. The T(3213)C and MspI, and the A(3235)C and SstI SNPs were in complete linkage disequilibrium, resulting in two different major haplotypes 2-2-1-2-2-1 and 1-1-2-2-2-2 (MspI-T(3213)C-A(3235)C-T(3287)C-A(5132)C-SstI). Both haplotypes appear to predispose to FCHL independently, and account, together with the wild-type, for almost 90% of those occurring in these FCHL families, extending the high-risk combination of haplotypes that were reported previously. CONCLUSION These newly identified additional intergenic SNPs therefore provide an alternative explanation for the observed association of the SstI and MspI polymorphisms to the increased susceptibility for FCHL.
Collapse
Affiliation(s)
- M Groenendijk
- Department of Internal Medicine, University Medical Center Utrecht, 3508 GA Utrecht, the Netherlands
| | | | | | | |
Collapse
|
44
|
Dallinga-Thie GM, Groenendijk M, Blom RN, De Bruin TW, De Kant E. Genetic heterogeneity in the apolipoprotein C-III promoter and effects of insulin. J Lipid Res 2001. [DOI: 10.1016/s0022-2275(20)30278-9] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
45
|
Eurlings PM, van der Kallen CJ, Geurts JM, van Greevenbroek MM, de Bruin TW. Genetic dissection of familial combined hyperlipidemia. Mol Genet Metab 2001; 74:98-104. [PMID: 11592807 DOI: 10.1006/mgme.2001.3232] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Familial combined hyperlipidemia (FCHL) is the most common genetic hyperlipidemia in man. FCHL is characterized by familial clustering of hyperlipidemia and clinical manifestations of premature coronary heart disease, i.e., before the age of 60. Although FCHL was delineated about 25 years ago, at present the FCHL phenotype and its complex genetics are not fully understood. Initially, the familial aggregation of high plasma total cholesterol and triglyceride levels, with a bimodal distribution of triglycerides, was taken as evidence of a dominant mode of inheritance. However, it is now clear that the genetics of FCHL is more complex, and it has been suggested that FCHL is heterogeneous. Several approaches can be taken to identify genes contributing to the disease phenotype in complex genetic disorders either by studying the disease in the human situation or by using animal models. Recent reports have shown that a combination of genetic linkage studies, association studies, and differential gene expression studies provides a useful tool for the genetic dissection of complex diseases. Therefore, the genetic strategies that will be used to dissect the genetic background of FCHL are reviewed.
Collapse
Affiliation(s)
- P M Eurlings
- Cardiovascular Research Institute Maastricht, University of Maastricht, Maastricht, The Netherlands
| | | | | | | | | |
Collapse
|
46
|
Voors-Pette C, de Bruin TW. Excess coronary heart disease in Familial Combined Hyperlipidemia, in relation to genetic factors and central obesity. Atherosclerosis 2001; 157:481-9. [PMID: 11472750 DOI: 10.1016/s0021-9150(00)00752-8] [Citation(s) in RCA: 48] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
AIM To determine the prevalence of non-fatal coronary artery disease (CAD) in kindred with Familial Combined Hyperlipidemia (FCHL) in relation to various cardiovascular risk factors and DNA variation in the apo AI-CIII-AIV gene cluster. METHODS AND RESULTS Data were collected from 18 Dutch FCHL probands, 202 living first and second degree relatives, and 175 spouses. Probands and first degree relatives showed dyslipidemia, increased plasma insulin and glucose concentrations, higher waist--hip ratio (WHR), and blood pressure, than spouses. The frequency of the minor alleles M2 and S2 was increased in probands and first degree relatives. The Odds Ratio for CAD was 5.3 in male FCHL relatives (P=0.005), and 5.1 in all FCHL relatives (P=0.001). First and second degree relatives had a markedly reduced CAD-free life-span (logrank vs. spouses: P<0.001 and P=0.03, respectively). The presence of the S2, but not M2, minor allele, showed a marked reduction in CAD-free life-span (logrank S2 present vs. S2 absent: P=0.035). CONCLUSION Men with FCHL have a severely increased risk of CAD, that appears to be mediated through genetic relation to the proband as the strongest independent risk factor for CAD, followed by increased WHR.
Collapse
Affiliation(s)
- C Voors-Pette
- Department of Medicine and Endocrinology and Cardiology Research Institute Maastricht, Academic Hospital Maastricht, PO Box 5800, 6202 AZ, Maastricht, The Netherlands
| | | |
Collapse
|
47
|
Abstract
Apolipoprotein (apo)C-I and apoC-III are constituents of HDL and of triglyceride-rich lipoproteins that slow the clearance of triglyceride-rich lipoproteins by a variety of mechanisms. ApoC-I is an inhibitor of lipoprotein binding to the LDL receptor, LDL receptor-related protein, and VLDL receptor. It also is the major plasma inhibitor of cholesteryl ester transfer protein, and appears to interfere directly with fatty acid uptake. ApoC-III also interferes with lipoprotein particle clearance, but its principal role is as an inhibitor of lipolysis, both through the biochemical inhibition of lipoprotein lipase and by interfering with lipoprotein binding to the cell-surface glycosaminoglycan matrix where lipolytic enzymes and lipoprotein receptors reside. Variation in the expression of apoC-III has been credibly documented to have an important role in hypertriglyceridemia. Variation in the expression of apoC-I may also be important for hypertriglyceridemia under certain circumstances.
Collapse
Affiliation(s)
- N S Shachter
- Divisions of Preventive Medicine and Nutrition, and Cardiology, Columbia University, New York, New York 10032-3702, USA.
| |
Collapse
|
48
|
Breslow JL. Genetics of lipoprotein abnormalities associated with coronary artery disease susceptibility. Annu Rev Genet 2001; 34:233-254. [PMID: 11092828 DOI: 10.1146/annurev.genet.34.1.233] [Citation(s) in RCA: 98] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Coronary heart disease is a complex genetic disease with many genes involved, environmental influences, and important gene-environment interactions. This review discusses the genetic basis of the principal lipoprotein abnormalities associated with coronary heart disease susceptibility in the general population. Individual sections discuss genes regulating LDL cholesterol, HDL cholesterol, and triglyceride levels. A section is included on the effects of the common apo E genetic variation on lipoprotein levels, as well as sections on the genetic regulation of lipoprotein(a) levels, genes regulating the inverse relationship between triglyceride-rich lipoproteins and HDL cholesterol levels, and our current understanding of the genetic basis of familial combined hyperlipidemia. It is clear that the field has progressed, with early studies focused mainly on the association of candidate gene RFLPs with phenotypes, later studies of candidate genes in both parametric and nonparametric linkage studies, and now more and more studies combining linkage analysis with genome scans to identify new loci that influence lipoprotein phenotypes. The future should provide us with the capability to perform reasonable genetic profiling for lipoprotein abnormalities associated with coronary heart disease susceptibility.
Collapse
Affiliation(s)
- J L Breslow
- Laboratory of Biochemical Genetics and Metabolism, The Rockefeller University, 1230 York Avenue, New York, NY 10021, USA.
| |
Collapse
|
49
|
|
50
|
Ylitalo K, Large V, Pajukanta P, Reynisdottir S, Porkka KV, Vakkilainen J, Nuotio I, Taskinen MR, Arner P. Reduced hormone-sensitive lipase activity is not a major metabolic defect in Finnish FCHL families. Atherosclerosis 2000; 153:373-81. [PMID: 11164426 DOI: 10.1016/s0021-9150(00)00410-x] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
The pathogenetic mechanisms behind familial combined hyperlipidemia (FCHL) are unknown. However, exaggerated postprandial lipemia and excessive serum free fatty acid (FFA) concentrations have drawn attention to altered lipid storage and lipolysis in peripheral adipose tissue. Hormone-sensitive lipase (HSL) is the enzyme responsible for intracellular lipolysis in adipocytes and a decrease of adipocyte HSL activity has been demonstrated in Swedish FCHL subjects. The aim of the study was to investigate if adipose tissue HSL activity had any effect on lipid phenotype and if low HSL activity and FCHL were linked in Finnish FCHL families. A total of 48 family members from 13 well-characterized Finnish FCHL families and 12 unrelated spouses participated in the study. FCHL patients with different lipid phenotypes (IIA, IIB, IV) did not differ in adipose tissue HSL activity from each other or from the 12 normolipidemic spouses (P = 0.752). In parametric linkage analysis using an affecteds-only strategy the low adipose tissue HSL activity was not significantly linked with FCHL phenotype. However, we found a significant sibling-sibling correlation for the HSL trait (0.51, P < 0.01). Thus, a modifying or interacting role of HSL in the pathogenesis of FCHL could not be excluded.
Collapse
Affiliation(s)
- K Ylitalo
- Department of Medicine, University of Helsinki, Finland
| | | | | | | | | | | | | | | | | |
Collapse
|